US20060002856A1 - Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129Xe - Google Patents
Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129Xe Download PDFInfo
- Publication number
- US20060002856A1 US20060002856A1 US11/224,204 US22420405A US2006002856A1 US 20060002856 A1 US20060002856 A1 US 20060002856A1 US 22420405 A US22420405 A US 22420405A US 2006002856 A1 US2006002856 A1 US 2006002856A1
- Authority
- US
- United States
- Prior art keywords
- polarized
- membrane
- evaluating
- gas
- barrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- FHNFHKCVQCLJFQ-YPZZEJLDSA-N xenon-129 atom Chemical compound [129Xe] FHNFHKCVQCLJFQ-YPZZEJLDSA-N 0.000 title claims abstract description 160
- 238000000034 method Methods 0.000 title claims abstract description 99
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 30
- 238000001727 in vivo Methods 0.000 title claims abstract description 26
- 210000000056 organ Anatomy 0.000 title claims description 9
- 206010007558 Cardiac failure chronic Diseases 0.000 title claims description 4
- 238000011156 evaluation Methods 0.000 title description 14
- 230000002612 cardiopulmonary effect Effects 0.000 title description 4
- 230000004962 physiological condition Effects 0.000 title 1
- 239000012528 membrane Substances 0.000 claims abstract description 74
- 230000004888 barrier function Effects 0.000 claims abstract description 55
- 239000003814 drug Substances 0.000 claims abstract description 16
- 230000003788 cerebral perfusion Effects 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 208000035475 disorder Diseases 0.000 claims abstract description 14
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 6
- 210000004369 blood Anatomy 0.000 claims description 85
- 239000008280 blood Substances 0.000 claims description 85
- 210000004379 membrane Anatomy 0.000 claims description 75
- 210000001519 tissue Anatomy 0.000 claims description 59
- 210000004072 lung Anatomy 0.000 claims description 44
- 239000000126 substance Substances 0.000 claims description 44
- 210000004556 brain Anatomy 0.000 claims description 43
- 230000010412 perfusion Effects 0.000 claims description 41
- 230000002685 pulmonary effect Effects 0.000 claims description 34
- 230000005284 excitation Effects 0.000 claims description 33
- 230000010287 polarization Effects 0.000 claims description 33
- 230000006399 behavior Effects 0.000 claims description 19
- 229910052756 noble gas Inorganic materials 0.000 claims description 16
- 238000004590 computer program Methods 0.000 claims description 14
- 210000002216 heart Anatomy 0.000 claims description 14
- 230000008499 blood brain barrier function Effects 0.000 claims description 12
- 210000001601 blood-air barrier Anatomy 0.000 claims description 11
- 238000009423 ventilation Methods 0.000 claims description 11
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 10
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 10
- 210000005166 vasculature Anatomy 0.000 claims description 10
- 230000002490 cerebral effect Effects 0.000 claims description 8
- 210000004884 grey matter Anatomy 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 210000004885 white matter Anatomy 0.000 claims description 7
- 210000005152 placental membrane Anatomy 0.000 claims description 5
- 238000003860 storage Methods 0.000 claims description 5
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
- 206010061818 Disease progression Diseases 0.000 claims description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 3
- 208000033626 Renal failure acute Diseases 0.000 claims description 3
- 201000011040 acute kidney failure Diseases 0.000 claims description 3
- 208000012998 acute renal failure Diseases 0.000 claims description 3
- 208000020832 chronic kidney disease Diseases 0.000 claims description 3
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 3
- 230000001010 compromised effect Effects 0.000 claims description 3
- 230000005750 disease progression Effects 0.000 claims description 3
- 210000005086 glomerual capillary Anatomy 0.000 claims description 3
- 230000024924 glomerular filtration Effects 0.000 claims description 3
- 238000009826 distribution Methods 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 210000003484 anatomy Anatomy 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 230000037081 physical activity Effects 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 abstract description 37
- 238000012544 monitoring process Methods 0.000 abstract description 12
- 238000011282 treatment Methods 0.000 abstract description 9
- 238000012216 screening Methods 0.000 abstract description 2
- 239000007789 gas Substances 0.000 description 106
- 230000006870 function Effects 0.000 description 40
- 239000012071 phase Substances 0.000 description 39
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 29
- 229910052724 xenon Inorganic materials 0.000 description 28
- 238000003384 imaging method Methods 0.000 description 26
- 238000001228 spectrum Methods 0.000 description 23
- 238000002595 magnetic resonance imaging Methods 0.000 description 18
- 230000017531 blood circulation Effects 0.000 description 15
- 238000004611 spectroscopical analysis Methods 0.000 description 14
- 210000005013 brain tissue Anatomy 0.000 description 11
- 210000001736 capillary Anatomy 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 229910052783 alkali metal Inorganic materials 0.000 description 8
- 150000001340 alkali metals Chemical class 0.000 description 8
- 230000003595 spectral effect Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 7
- 238000009792 diffusion process Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 150000002835 noble gases Chemical class 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000005415 magnetization Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 201000009906 Meningitis Diseases 0.000 description 4
- 230000003727 cerebral blood flow Effects 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010014599 encephalitis Diseases 0.000 description 4
- 210000005240 left ventricle Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000004535 dynamic nuclear magnetic resonance Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 201000008191 cerebritis Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000003989 endothelium vascular Anatomy 0.000 description 2
- 230000005283 ground state Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 238000004480 129Xe NMR spectroscopy Methods 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010037765 Radiation pneumonitis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 244000025271 Umbellularia californica Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- -1 amphetamines Chemical compound 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000036978 cell physiology Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 210000001038 distal kidney tubule Anatomy 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007792 gaseous phase Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- SWQJXJOGLNCZEY-BJUDXGSMSA-N helium-3 atom Chemical compound [3He] SWQJXJOGLNCZEY-BJUDXGSMSA-N 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 238000013125 spirometry Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000003270 subclavian artery Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/483—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy
- G01R33/485—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy based on chemical shift information [CSI] or spectroscopic imaging, e.g. to acquire the spatial distributions of metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/563—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution of moving material, e.g. flow contrast angiography
- G01R33/56308—Characterization of motion or flow; Dynamic imaging
Definitions
- the present invention relates to magnetic resonance imaging (“MRI”) and MR spectroscopy using hyperpolarized noble gases. More particularly, the present invention relates to techniques to assess certain physiology, conditions, and/or functions of organs or body systems in vivo using polarized noble gases.
- MRI magnetic resonance imaging
- MR spectroscopy using hyperpolarized noble gases. More particularly, the present invention relates to techniques to assess certain physiology, conditions, and/or functions of organs or body systems in vivo using polarized noble gases.
- hyperpolarizers are used to produce and accumulate polarized noble gases.
- Hyperpolarizers artificially enhance the polarization of certain noble gas nuclei (such as 129 Xe or 3 He) over the natural or equilibrium levels, i.e., the Boltzmann polarization.
- MRI Magnetic Resonance Imaging
- the hyperpolarizer in order to produce the hyperpolarized gas, is configured such that the noble gas is blended with optically pumped alkali metal vapors such as rubidium (“Rb”). These optically pumped metal vapors collide with the nuclei of the noble gas and hyperpolarize the noble gas through a phenomenon known as “spin-exchange”.
- the “optical pumping” of the alkali metal vapor is produced by irradiating the alkali-metal vapor with circularly polarized light (typically provided by lasers) at the wavelength of the first principal resonance for the alkali metal (e.g., 795 nm for Rb). Generally described, the ground state atoms become excited, then subsequently decay back to the ground state.
- the alkali-metal vapor atoms can collide with the noble gas atoms in a manner in which the polarization of the valence electrons is transferred to the noble-gas nuclei through a mutual spin flip “spin-exchange”.
- the hyperpolarized gas is separated from the alkali metal prior to introduction into a patient.
- gas-phase imaging has been possible using both 3 He and 129 Xe, and has been particularly useful in producing ventilation-driven images of the lungs, a region where proton images have produced signal voids.
- dissolved phase imaging has proven to be problematic. Dissolved phase imaging uses the solubility characteristic of 129 Xe in blood and lipid rich tissue. The gas phase is thus absorbed or “dissolved” into surrounding tissue or blood vessels and may allow perfusion imaging of the brain, lung, or other regions. Such images can potentially allow for the performance of non-invasive studies of the pulmonary vasculature to detect emboli and other circulatory system problems.
- the polarized gas has been dissolved (such as into the blood vessels), it has proven difficult to generate clinically useful images using the dissolved phase gas.
- MRI images using gas-space-imaging techniques have been generated using hyperpolarized 129 Xe gas. See Mugler III et al., MR Imaging and Spectroscopy Using Hyperpolarized 129 Xe gas: Preliminary Human Results, 37 Magnetic Resonance in Medicine, pp. 809-815 (1997). While good correlation is seen between the gas-space signal in the xenon images and the gas-space signal void in the proton images, the spectra associated with the dissolved phase signal components were significantly lower than the gas-phase signal.
- methods of the present invention obtain dynamic NMR spectroscopy signal data that corresponds to the behavior of polarized 129 Xe at a selected site(s) or environment in vivo.
- the signal data can be used to evaluate: (a) the physiology (tissue volume or thickness/width) of a membrane, organ, tissue, or other physiological structure or environment; (b) the operational condition or function of a membrane, body system, or portion thereof; (c) cerebral perfusion; and/or (c) the efficacy of a therapeutic treatment used to treat a diagnosed disorder, disease, or condition.
- the present invention provides methods for screening and/or diagnosing a disorder or disease, and/or methods for monitoring the efficacy of therapeutics administered to subject to treat a disorder or disease.
- a curve can be best-fit to the dynamic data to represent the behavior of the polarized 129 Xe at selected chemical shifts or frequencies.
- the curve can have various characterizing parameters including: an associated time constant, peak amplitude, amplitude at the time constant, slope of linear portions, and the like. These characterizing parameters can be used to evaluate the target of interest.
- the curve can illustrate the transit time of polarized 129 Xe in a target in the body. Delayed (longer) transit times may represent thicker tissue, or poor perfusion to help evaluate whether the subject may be hypoxic (in one or more areas such as in the pulmonary blood, the cardiac region, or in the brain).
- the polarized 129 Xe can be used to determine whether low oxygen saturation is the result of poor ventilation, poor perfusion, and/or poor gas diffusing capacity across tissue or membranes. Such an analysis can be used to monitor therapeutic efficacy or disease progression.
- a dynamic data set of the signal strength of the 129 Xe in selected tissue or environments over time can be generated and evaluated. Such information can be used in various manners such as to assess perfusion uptake, or the function of selected membranes, linings, and biosystems.
- the dynamic data set corresponds to the accrual, build up, or increase in signal strength over time of 129 Xe at one or more chemical shift frequencies or ppm.
- Particular embodiments of the present invention are directed to minimally or non-invasive in vivo methods for evaluating the thickness or width of a physiological barrier such as a membrane, lining, lumen, channel, or wall in a subject using polarized 129 Xe.
- the method includes: (a) delivering polarized 129 Xe gas in vivo to a subject having a first environment, a physiological barrier having a thickness, and a second environment opposing the first environment such that the polarized 129 Xe travels serially through the first environment, the barrier, and into the second environment, wherein the polarized 129 Xe has an associated different NMR signal chemical shift frequency in the first and second environments and the barrier; (b) destroying the polarization of the 129 Xe in the barrier and the second environment; (c) obtaining an NMR spectroscopic signal of the polarized gas in the subject at the second chemical shift to generate at least one dynamic data set of the NMR spectroscopic signal strength values over time representative of the behavior of the
- the method may further include (a) generating a signal strength versus time curve to fit the dynamic data; (b) identifying a time constant of the curve; and (c) evaluating the amplitude of the signal strength at a time along the curve corresponding to the time constant.
- the operation or function of the membrane can be evaluated without determining the thickness of the membrane.
- the method can be used to measure membranes having a thickness in the range of about 1 micron to about 100 microns.
- Another embodiment is directed to in vivo methods for evaluating the blood brain barrier in a subject.
- the method comprises: (a) delivering polarized 129 Xe in vivo to a subject such that it diffuses into the blood stream, across the blood brain membrane, and is taken up in tissue in the brain across the membrane, the polarized gas in the blood, membrane, and brain tissue having distinct corresponding polarized gas NMR chemical shift signal frequencies; (b) destroying the polarization of the polarized 129 Xe in at least the brain tissue; (c) obtaining an NMR spectroscopic signal of the polarized gas in the subject over time at the brain tissue chemical shift frequency to generate at least one dynamic data set of the NMR spectroscopic signal strength values over time; (d) evaluating the dynamic data; and (e) assessing the blood brain barrier based on data provided by the obtaining and evaluating steps.
- inventions of the present invention are directed at methods for monitoring gas exchange dynamics of 129 Xe at or across the blood brain barrier to evaluate inflammatory disorders of the brain such as meningitis, encephalitis, and the like and/or to provide methods that can distinguish between certain disorders such as between meningitis and cerebritis by analyzing the gas exchange reaction at the blood barrier membrane. Still other embodiments are directed to measurement of organ perfusion by monitoring xenon transport in, to, or through, that organ.
- Still other embodiments are directed to methods of obtaining cerebral perfusion information.
- the method comprises: (a) administering polarized 129 Xe to a subject in vivo; (b) concurrently obtaining a plurality dynamic data sets of NMR spectrographic signal strength of the polarized 129 Xe in a compartment of the brain of the subject representative of perfusion in the brain, each dynamic data set corresponds to a different chemical shift frequency; (c) repeating step (b) for a plurality of different compartments across the brain; and (d) generating at least one perfusion image of the brain based on the data provided by the obtaining steps, wherein the image comprises a plurality of voxels associated therewith, and wherein each voxel corresponds to a measure of perfusion in the associated compartment in the brain.
- inventions are directed to in vivo methods for evaluating at least one of the thickness of adequacy of function of a membrane or lining, comprising: (a) delivering polarized 129 Xe in vivo to a subject such that the polarized 129 Xe moves across the membrane or wall, the polarized gas in the membrane or wall having a corresponding polarized gas NMR chemical shift signal frequency; (b) obtaining an NMR spectroscopic signal of the polarized gas in the subject over time at the chemical shift frequency to generate at least one dynamic data set of the NMR spectroscopic signal strength values over time; and (c) evaluating at least one of (1) the adequacy of function of the membrane or lining and (2) the thickness of the membrane or lining based on the data provided by said obtaining step.
- the computer program product includes computer readable storage medium having computer readable program code embodied in the medium, the computer-readable program code comprises: (a) computer readable program code that obtains an NMR spectroscopic signal of polarized 129 Xe in the subject over time at at least one selected chemical shift frequency to generate at least one dynamic data set of the NMR spectroscopic signal strength over time; and (b) computer readable program code that analyzes the dynamic data set for at least one of: (a) quantifying the thickness of a physiologic barrier such as a tissue, membrane, or lining of interest (b) quantifying the width of a lumen or channel; (c) evaluating the adequacy of physiologic function of certain biosystems or membranes; (d) identify disruptions or compromised integrity of physiological barriers, structures, lumens, or channels and/or to identify disorders associated therewith; and (e) to provide a
- the instant invention can use spectroscopic or MRI imaging techniques to obtain signal data corresponding to a quantity of dissolved polarized 129 Xe before and after a physiologically active substance is administered to a human or animal body to evaluate the efficacy of the drug treatment.
- embodiments of the present invention may include methods, systems and/or computer program products.
- FIG. 1 is a graph of 129 Xe spectra showing the spectral signal of different chemical shifts of polarized xenon in blood and tissue.
- FIG. 2A is a schematic illustration of polarized gas distributed into two proximate regions in the body according to embodiments of the present invention.
- FIG. 2B is a simulated graph illustrating the chemical shifts associated with the two regions shown in FIG. 2A .
- FIG. 2C is a graph of signal strength as a function of time of the polarized gas in region two of FIG. 2A according to embodiments of the present invention.
- FIG. 3A is a micrograph of lung tissue and alveoli structure.
- FIG. 3B is an enlarged micrograph of alveolar structure illustrating the capillary and alveolar air space and red blood cells.
- FIG. 4 is a graph illustrating the uptake of polarized 129 Xe in blood over time according to embodiments of the present invention.
- FIG. 5A is a simulated graph of the signal of the 129 Xe blood component over time according to embodiments of the present invention.
- the signal amplitude in blood is shown as one of the peaks of interest in FIG. 1 .
- FIG. 5B is a simulated graph of the signal of the 129 Xe tissue component over time according to embodiments of the present invention.
- the signal amplitude in tissue is shown as one of the peaks of interest in FIG. 1 .
- FIG. 6 is a graph of the uptake of polarized 129 Xe in blood over time.
- the graph illustrates three different curves fit to the dynamic data, each representing a different dynamic gas behavior which can be evaluated to ascertain information about the patient according to embodiments of the present invention.
- FIG. 7A is a polarized gas 129 Xe measure of ventilation distribution MRI image of the lungs and FIG. 7B is a graph of the polarized 129 Xe uptake over time; each can be generated based on a single-breath or ventilation administration of the polarized 129 Xe according to embodiments of the present invention.
- FIG. 8B is an image of the brain wherein each voxel (3-D pixel) represents/measures the perfusion associated with a plurality of NMR frequencies simultaneously according to embodiments of the present invention.
- FIGS. 8A and 8C illustrate the perfusion signal amplitude data at a plurality of frequencies for the chemical shifts of brain tissue and/or cerebral blood flow shown in FIG. 8B .
- FIG. 9 is a flow chart illustrating one embodiment of operations for a method for spectroscopic analysis according to the present invention.
- FIG. 10 is a flow chart illustrating one embodiment of operations for a method for spectroscopic analysis according to the present invention.
- FIG. 11 is a flow chart illustrating one embodiment of operations for a method for spectroscopic analysis according to the present invention.
- FIG. 12 is a flow chart illustrating one embodiment of operations for a method for spectroscopic analysis according to the present invention.
- polarized gases are collected, frozen, thawed, and used in MRI and NMR spectroscopy applications.
- frozen polarized gas means that the polarized gas has been frozen into a solid state.
- liquid polarized gas means that the polarized gas has been or is being liquefied into a liquid state.
- the term “gas” has been used in certain instances to descriptively indicate a hyperpolarized noble gas product and may be used with modifiers such as solid, frozen, dissolved, and liquid to describe the state or phase of that product.
- the hyperpolarized gas is processed such that it is a pharmaceutical grade product suitable for in vivo delivery to a human subject.
- the 129 Xe gas product is formulated to have less than about 10 ppb (parts per billion) alkali metal therein, and can have less than about 1 ppb.
- hyperpolarize As used herein, the terms “hyperpolarize,” “polarize,” and the like are used interchangeably and mean to artificially enhance the polarization of certain noble gas nuclei over the natural or equilibrium levels. Such an increase is desirable because it allows stronger imaging signals corresponding to better MRI images and spectroscopy signals of the gas in the body.
- hyperpolarization can be induced by spin-exchange with an optically pumped alkali-metal vapor or alternatively by metastability exchange. See Albert et al., U.S. Pat. No. 5,545,396.
- NMR signal strength spectrum data (obtained in vivo) of polarized 129 Xe in the body of a subject is illustrated.
- the dissolved-phase spectra are shown on the left side of the figure (indicated by peaks at f 1 and f 2 ).
- the gas-phase spectra (on the right side of the figure at “0”) have a larger signal relative to the spectra of the 129 Xe dissolved in blood or tissue.
- a quantity of polarized 129 Xe is inhaled into the lungs, a small fraction of this gas (roughly about 0.3% per/second) transits into the pulmonary blood.
- polarized 129 Xe in the lung exhibits three distinct NMR resonances: 0 parts per million (“ppm”) is associated with gaseous 129 Xe, 197 ppm is associated with 129 Xe dissolved in lung tissue (f 1 ), and 212 ppm is associated with 129 Xe dissolved in blood (f 2 ).
- ppm parts per million
- Table 1 listed hereinbelow illustrates examples of NMR resonances of additional bio-substances.
- Signal strength for the selected resonances can be tracked as a function of time with at least about millisecond resolution.
- Other peaks at other locations, environments, tissues or membranes in the body may be selected in other embodiments.
- the present invention monitors the behavior of the polarized 129 Xe in the body by obtaining the signal strength over time between or at certain regions of the body to ascertain certain physiologic, performance, or systemic function information.
- polarized 129 Xe is administered to a subject such that it is present in proximate regions, i.e., region 1 (identified by the number 1), and region 2 (identified by the number 2).
- region 1 and region 2 can be separated by a barrier 10 such as a wall, membrane, tissue or other structure.
- the polarized gas in region 1 has a chemical shift which is distinct from the polarized gas into region 2 .
- the barrier 10 can also have a signal with its own chemical shift.
- the polarized gas in region 1 (either in gaseous or dissolved state) can travel or diffuse to, and hence supply, the polarized gas in region 2 .
- the build-up of signal of the polarized gas in region 2 can be dynamically monitored.
- the transit time can be described as the time it takes for the polarized gas to cross the barrier 10 in sufficient quantities or amounts to yield a detectable signal and/or to approach a substantially steady state condition in signal strength therefrom.
- a curve or line can be statistically “best-fit” to the dynamic data or signal strength over time.
- the line or curve will have an associated time constant ( ⁇ ) which can be used to represent the transit time of the gas through the barrier 10 .
- ⁇ time constant
- the curve or line will have other characterizing parameters which are measurable or representative of physiologic condition, structure, or function, as will be discussed more below.
- the polarization, and hence the signal, in region 2 can be destroyed (such as by transmitting a large RF excitation signal to that region) and then the signal in region 2 can be monitored as the signal strength of the chemical shift spectra of the polarized gas entering region 2 rebuilds from the ongoing supply of polarized gas delivered thereto during the analysis period.
- FIG. 2C illustrates that the dynamic data can be generated with sufficient resolution to be able to measure uptake with sufficient resolution to obtain data points of signal strength over time to define a slope or line shape corresponding to the dynamic behavior of the polarized 129 Xe in the tissue, region, or barrier.
- the dynamic data can be obtained so as to provide signal strength data for a time which is at least twice the time constant to allow for a sufficient number of data points to render a representative line or curve.
- the time constants typically range from about 0.25 ms to about 2.5 seconds.
- a dynamic data set of NMR spectroscopic blood signal strength of polarized 129 Xe in an environment of interest (such as blood) over time at at least one chemical peak or shift of interest can be obtained and evaluated to assess certain physiological parameters, structures, or function of the structure or body systems or portions thereof (nervous system, circulatory, respiratory, or cerebral).
- the parameters can include, but are not limited to, one or more of perfusion uptake, the function or integrity of a physiologic structure such as a membrane, lining, or wall, and/or the thickness of the barrier or structure, including the membrane, lining, wall or the width of a lumen (such as a capillary or other lumen), red blood cell, or a body cavity.
- Characterizing parameters provided by the dynamic data include the time it takes the polarized gas to travel through the barrier or a selected tissue or environment (i.e., the transit time which can be represented by a calculated time constant as noted above), the oxygen saturation level or measure of ventilated blood volume (as a measure of shunt) in the patient.
- the dynamic data set corresponds to the accrual, build up, or increase in signal strength of a particular signal or signals with an associated chemical shift (such as in the pulmonary blood, the cerebral blood, or alveolar tissue), over time.
- FIG. 3A is a micrograph of lung tissue or alveolar structure.
- FIG. 3B is enlarged (20 ⁇ ) compared to the scale shown in FIG. 3A and illustrates alveolar structure including the alveolar epithelium (Ep), the interstitium (Ei), the capillary endothelium (En), a capillary (C) and red blood cell (R) and alveolar air space (A).
- the present invention provides methods for evaluating gas transit behavior across lung tissue, and/or across the alveolar-capillary membrane into the pulmonary blood.
- this information can be used to evaluate chronic heart failure (“CHF”) because CHF typically disturbs the alveolar-capillary membrane and increases the resistance to polarized gas transfer as the gas attempts to travel toward the pulmonary blood (into the red blood cells). Elevation of the capillary pressure can increase the capillary permeability to water and ions and disrupt local regulatory mechanisms for gas exchange, leading to thickening of the alveolar-capillary interstitium, and/or to a decrease in membrane conductance and subsequent impairment of diffusion capacity.
- CHF chronic heart failure
- Monitoring of the transit time and/or behavior of 129 Xe acting as a tracer across a membrane in resting conditions and during (incremental) actual or simulated exercise (and/or after administration of a pharmaceutical product or therapeutic agent) can be performed so as to measure the function of the alveolar-capillary membrane.
- Other physiology or structures, membranes, or other barriers and associated peaks and regions can be monitored for other conditions as noted above.
- FIG. 5A illustrates the signal strength of the 129 Xe in blood (f 2 ) over time and FIG. 5B illustrates the signal strength of the 129 Xe in tissue (f 1 ) over time.
- a series of increasingly longer pulses are transmitted to generate the response signal.
- a plurality of different dynamic data sets, each at different discrete frequencies or chemical shifts can be obtained concurrently.
- polarized 129 Xe is administered to the subject or patient. Then the polarization of the polarized 129 Xe can be destroyed in a selected in vivo environment, structure, or physiology and then allowed to rebuild. For example, gaseous polarized 129 Xe can be inhaled into the lungs and then the 129 Xe can diffuse to, and hence supply, the polarized 129 Xe into the membrane (as it diffuses serially across Ep, Ei, and then En) and into the capillary and the pulmonary blood.
- the build up of signal of the polarized 129 Xe in a selected environment can be dynamically monitored to determine a time constant “ ⁇ ” associated with transit time of the polarized 129 Xe as it diffuses across the environment of interest (such as a lining, wall, or membrane).
- NMR signal strength data of the polarized 129 Xe is collected for a first time period. The signal strength of the chemical shift spectra of the polarized gas entering the blood increases over time as it rebuilds from “0” from the ongoing supply of polarized gas delivered from the lungs during the analysis period.
- the polarization is destroyed each time and then the response data is collected at successively longer times to collect the signal data at the desired times in the analysis period.
- the NMR data can be collected using decremented pulse intervals (starting with the longest interval and moving to the shortest) or other sequences as desired.
- the data can be collected and the response curve of the 129 Xe can be generated using curve fit using statistical analysis techniques well known to those of skill in the art. Other peaks at other locations, environments, tissues or membranes in the body may be selected in other embodiments and similarly evaluated for function.
- FIGS. 5A and 5B illustrate that the dynamic data can be generated with sufficient resolution to measure uptake with sufficient resolution to define a line shape corresponding to the uptake of the 129 Xe.
- the signal data can be collected for times that are at least two times that of the time constant.
- time constant “ ⁇ ” can be used to determine the thickness or width of the barrier.
- the glomerular capillary membrane can be evaluated by administering polarized 129 Xe to assess for any disruptions, apertures, permeability and flow rate across this membrane to give a quantitative assessment in health and disease.
- One result may be to record glomerular filtration rate and this could be given globally or for each individual kidney. This is useful in many clinical situations, e.g., measuring GFR prior to chemotherapy administration.
- the disease affects the structure and function of the membrane so the methods of the present invention can be used to monitor disease progression and effect of therapy.
- the disorders involved here may be acute and chronic renal failure, nephrotic syndrome, glomerulonephritis and other renal diseases.
- the proximal or distal renal tubules may be evaluated using polarized 129 Xe.
- the function of the large and/or small bowel wall can be evaluated.
- a quantitative assessment of bowel membrane integrity and function may be useful in a variety of gastroenterological diseases.
- the placental membrane may be evaluated.
- the polarized 129 Xe may be administered to the mother via inhalation or injection proximate to the placental membrane itself.
- a minimally or non-invasive method of assessing placental integrity and function other using 129 Xe can provide additional information over conventional techniques (such as to observe the consequences of poor function by measuring fetal growth). Such a method of giving quantitative placental function may be a useful clinical tool in obstetrics.
- the blood brain barrier can be evaluated so as to quantify or evaluate the integrity and function of this barrier or conditions associated therewith.
- the evaluation of the blood brain barrier can be to evaluate thickness or function or to assess for inflammatory disorders of the brain such as meningitis, encephalitis, and the like and/or to provide methods that can distinguish between certain disorders such as between meningitis and cerebritis by analyzing the gas exchange reaction at the blood barrier membrane.
- Other embodiments include assessing blood cell physiology or function defects or abnormalities (such as evaluating the presence or degree of sickle cell anemia).
- the uptake into a barrier, blood, or tissue can be measured as a function of time.
- the initial build-up rate (after the polarization is substantially destroyed in the membrane and the blood) of the xenon/blood or xenon/tissue signal is sensitive to barrier thickness.
- the spectroscopic signal of the xenon/blood or xenon/tissue can be used to quantify the thickness and/or the degree of edema or the function or thickness of the barrier associated with various conditions.
- the quantified or estimated thickness of the barrier membrane and/or the initial data associated with the gas exchange during the initial build up can also be used to evaluate other conditions as noted above.
- the response or behavior of the 129 Xe during other portions of the analysis period can be used to evaluate ventilation/perfusion ratios.
- the curve or line shown can be broken down into at least three characterizing parameter: the slope “m” corresponding to the linear rise in the signal after the initial portion of the signal, the time constant “ ⁇ ” associated with the initial portion of the signal, and the amplitude defined by a steady state amplitude of the signal deconvoluted from the data representing the signal at the t>> than the calculated time constant “ ⁇ ”.
- the slope “m” can be used as a measure of global xenon uptake (as a tracer for oxygen) in the blood.
- the slope of this curve (“m”) may yield information about global blood flow to the ventilated portion of the lung and, hence, may be a predictor of shunt or cardiac output.
- the amplitude of the 129 Xe spectroscopic signal defined in relationship to the time constant can be used as a measure of oxygen saturation (ventilated blood volume).
- the time constant “ ⁇ ” can also be used to evaluate or determine the thickness, function, or physiology of the barrier or membrane.
- the NMR signal of 129 Xe in tissue can also be monitored to evaluate tissue volume (corresponding to the peak amplitude of the curve associated therewith) while the time constant “ ⁇ ” associated with the signal in tissue can be used as a measure of thickness.
- the measured thickness can range from about 1 um-100 um.
- the NMR signals and associated evaluations and measurements can be performed while the subject is substantially at rest and/or when the subject or patient is exposed to stress such as while exercising (or exposed to artificial stimulus elevating the heart beat rate and/or emulating other cardiopulmonary conditions).
- the dynamic data provided by the polarized 129 Xe an be used to monitor a therapy administered to the subject for efficacy or for drug development processes where a new drug or use is undergoing evaluation during clinical or pre-clinical trials.
- FIGS. 5A and 5B illustrate simulated signal strength (peak area) in % over successively longer incrementally increasing inter-pulse delay times.
- the xenon transit time into the monitored frequency shift occurs at the initial portion of the curve.
- S xenon/blood resonance signal
- S(t) xenon/tissue resonance (or other environment of interest)
- S(t) S 0 (1 ⁇ e ⁇ t/ ⁇ ). Equation (1)
- ⁇ is the time constant for polarized 129 Xe associated with the uptake and/or dissolved gas-exchange transit time
- S is the signal strength of the polarized 129 Xe at the selected frequency (or in the bio-environment or bio-structure of interest).
- Equation (2) The mean square distance traveled by a randomly diffusing gas can be approximated as described by Equation (2).
- Z 2 2Dt. Equation (2)
- D the diffusion coefficient constant
- t the time it takes the gas to diffuse through the membrane.
- FIG. 6 illustrates graphs of curves having three different time constants for the polarized 129 Xe signal in blood illustrating the cardiopulmonary functional change that may be representative of heart failure or other disorders, diseases, or conditions.
- the time constant can be calculated by Equation 1 and is typically defined at when the signal is at about 63% of its ultimate value.
- the time constant for each of the curves varies in a quantifiable manner.
- the alveolar membrane can thicken in response to hypertension or other conditions.
- the transit time or time constant “ ⁇ ” increases (shown as going from 70 ms to 300 ms) corresponding to the thickening of the alveolar membranes in response to hypertension and the like (reducing oxygen diffusing capability).
- Many therapeutic regimens attempt to change physiology of certain regions, organs, or structures of the body (such as to thin the alveolar membranes) and the present invention can assess whether this objective has been achieved by evaluating the time constant ⁇ and/or other 129 Xe signal parameter. Monitoring such a progression or behavior to confirm that the therapy is effective of that the condition is not deteriorating may provide important clinical information.
- the signal strength of the dissolved phase polarized xenon signal intensity versus repetition time can have an associated slope “m” which is a function of the signal and the pulse repetition (dS p /dT R ).
- a large flip angle pulse (preferably a flip angle of about 90 degrees) can be transmitted to the blood; this destroys all the magnetization in the xenon and, thus, the signal of the dissolved polarized xenon in the blood.
- additional polarized 129 Xe is taken-up in the blood (replenished) over time until a substantially steady state level is reached: the more polarized xenon in the blood, the larger or stronger the associated signal.
- This increase in the dissolved phase xenon signal over time (after the initial transit time across the barrier) can be mathematically represented by the slope of the line (dS p /dT R ).
- the slope (after an initial gas blood barrier crossing period) can be directly proportional to blood flow rate (Q) in the bloodstream.
- the data acquisition can obtain several data points such as three-ten temporally separate data points within the first 60 ms to establish the time constant associated with the curve fit of the signal shape/ 129 Xe behavior at the peak(s) of interest.
- the slope data of the dissolved phase polarized 129 Xe in tissue and/or blood versus can be adjusted by comparing it to the gas phase signal in the lung (S L ).
- This gas phase signal (S L ) is acquired from an excitation signal with a known flip angle ⁇ L (the polarized gas is conveniently available in the lung space).
- the present invention can use a mathematical relationship between the dissolved phase polarized xenon signal in the blood or tissue with the xenon signal in the gaseous phase in the lung to establish a quantitative measure of signal.
- a lung volume (V L ) is measured by conventional means before or after the MR procedures, or by assuming an average or normalized lung volume for a particular patient size or age. After a short initial time, the slope of the curve corresponds to the blood flow rate in the blood stream.
- the alveolar transit time, oxygen saturation level, global perfusion, tissue volume and ejection fraction can be evaluated to identify any abnormalities or alterations in physiology or function.
- the ventilated blood flows to the heart to the left atrium to the left ventricle and pumped to body through the (arch of) aorta.
- the blood is forced or ejected from the heart in pulsatile flow corresponding to the pumping action thereof.
- the pulsatile flow behavior of the blood ejected from the aorta can be monitored to evaluate or map the ejection fraction.
- Gradient-tagged RF excitation pulses can be used to look at the signal of the 129 Xe in the blood as it exits the aorta or left ventricle (or region proximate thereto).
- This targeted region can be monitored to obtain the signal strength of the 129 Xe in this ejected blood over time, the signal will increase and decrease corresponding to the cardiac cycle and the signal can be evaluated to assess how much of the polarized blood is pumped out of the left ventricle or aorta in each pumping cycle.
- This ejection fraction can be compared to the subject's own previous evaluation or based on a statistical population average (by gender and/or age which can be generally stated to be an average of about 60%) to asses whether there is an abnormality.
- a statistical population average by gender and/or age which can be generally stated to be an average of about 60%
- the ejection fraction may be identified as 50% (lower than average).
- the dynamic gas exchange data of signal over time in one, two, or more different environments, regions, or tissues can provide information on ventilation, perfusion, and ejection fraction, as noted above.
- the test can be carried out in an MRI magnet with a dual-tuned 129 Xe/ 1 H coil to allow conventional or standard imaging to be performed to yield anatomical information in the same MR imaging/spectroscopy session. It is noted that the image shown is based on polarized 3 He because it is readily accessible, but it is anticipated that a similar resolution ventilation image can be generated using polarized 129 Xe.
- the barrier 10 can be a wall, membrane, lining, tissue, red blood cell, or other structure, fluid, or environment in the body.
- the gas-exchange dynamics of membranes can be evaluated using the dynamic data sets of polarized 129 Xe.
- Particular embodiments of the present invention are directed to methods of evaluating the dynamic behavior of the polarized 129 Xe in a target region in the body to evaluate the cerebral perfusion of a subject, or other structures or membranes for dysfunctions.
- the polarized 129 Xe can be used to determine one or more of whether low oxygen saturation is the result of poor ventilation, poor perfusion, and/or poor gas diffusing capacity across the alveolar membrane.
- Such an analysis can be used to diagnose chronic heart failure, to differentiate uncertain aetiology of breathlessness such as to identify cardiac or respiratory origin, to determine the adequacy of the alveolar-capillary unit, and to monitor therapeutic efficacy of treatments on those conditions.
- the present invention allows for evaluations of the adequacy of the alveolar-capillary unit using polarized 129 Xe in a manner that can be useful to allow proper diagnosis and treatment.
- Potential clinical indications which can be assessed by methods of the present invention include, but are not limited to, the presence and/or extent of emphysema, the presence and/or extent of alveolitis (and follow-up monitoring for same), to differentiate pure airway conditions from conditions which affect the alveolar airspaces, the diagnosis of alveolar hemorrhagic conditions, and the diagnosis of radiation pneumonitis.
- FIGS. 8A-8C illustrate another exemplary embodiment, where regional cerebral perfusion can be evaluated.
- FIGS. 8A and 8C are spectra of the polarized xenon at different locations (compartments) in the brain.
- the various peaks in the spectroscopic spectrums illustrate that a plurality of dynamic data sets (one for each of two, or more peaks shown by the three arrows pointed at certain peak positions) may be concurrently obtained at each compartment. This can be repeated to provide a cerebral perfusion map. That is, a simultaneous presentation of multiple peaks associated with perfusion in the brain.
- the peaks may correspond to gray matter, white matter, and the like.
- the perfusion data provided by the dynamic data can be used to construct a perfusion image of the brain where each voxel measures or quantifies a perfusion of a number of compartments simultaneously with moderate resolution (shown as about 5 mm or 1 cm 3 ). Such information can evaluate regional cerebral blood flow, white matter perfusion, gray matter perfusion, demylenation, and hypoxia or stroke.
- the cerebral perfusion image can combine the signal strength information of the multiple data sets or can be used separately to provide three different perfusion maps of the brain based on data obtained concurrently.
- FIG. 9 is a flow chart of operations according to certain embodiments of the present invention.
- polarized 129 Xe is administered to a patient in vivo (block 100 ).
- At least one dynamic data set of signal strength over time of an NMR spectrographic signal of the polarized 129 Xe in the body of the patient is obtained at at least one selected chemical shift frequency (resonance) (block 120 ).
- a plurality of concurrent dynamic data sets can be obtained for different resonances, as desired.
- the polarization of the 129 Xe can be destroyed locally prior to the obtaining the dynamic data (block 122 ).
- the dynamic data can be evaluated to determine the thickness or width of a physiologic barrier such as a membrane, wall, or lumen (block 130 ).
- a curve of signal strength over time can be generated to statistically “best-fit” the dynamic data (block 133 ) and a time constant associated therewith can be determined (block 133 ).
- a therapeutic agent can be administered and the operations described in blocks 120 and 130 can be repeated. The data for each can be compared to evaluate any alterations in the thickness or width (block 140 ).
- the physiologic barrier can be the alveolar-capillary membrane (block 132 ) or other membranes, or linings, walls, lumens, or structures or fluid environments in the body.
- FIG. 10 illustrates the operations of another embodiment of the present invention.
- polarized 129 Xe is administered to a patient in vivo (block 200 ).
- At least one dynamic data set of an NMR spectrographic signal of the polarized 129 Xe in the body of the patient at at least one selected chemical shift frequency over time is obtained.
- the chemical shift frequency or resonance can be selected to correspond to brain tissue (such as gray matter or white matter).
- the polarization of the 129 Xe can be destroyed locally proximate the brain tissue prior to initiating the obtaining step (block 222 ).
- the dynamic data can be evaluated to determine at least one of the thickness or adequacy of the function of the blood brain barrier function (block 230 ).
- a curve can be generated to fit the dynamic data and certain characterizing parameters can be evaluated. For example, the time constant, selected amplitude(s) of the curve, the area under the curve, the slope associated with the perfusion uptake into the brain (white or gray matter or cerebral blood) (block 233 ).
- a therapeutic agent can be administered to the patient and the operations recited in blocks 220 and 230 can be repeated (block 240 ). The dynamic data from the first and repeated steps can be compared to evaluate efficacy or impact on the patient.
- polarized 129 Xe is delivered to the brain via the blood stream and crosses the blood brain barrier to diffuse into brain tissue.
- the polarization can be destroyed and then the NMR signal strength over time associated with uptake of 129 Xe in one or more brain tissue components can be monitored to assess blood brain barrier function and/or thickness or physiology.
- FIG. 11 is a flow diagram of operations of yet another embodiment.
- polarized 129 Xe is administered to the subject or patient (block 300 ).
- a plurality of dynamic data sets are obtained concurrently, each of the dynamic data sets being representative of a different chemical shift frequency of an NMR spectrographic signal of the polarized 129 Xe in the brain.
- the polarization of the 129 Xe can be destroyed prior to commencing the obtaining operation (block 322 ).
- At least one cerebral perfusion image can be generated mapping the perfusion in the brain associated with a plurality of different brain constituents (block 330 ).
- the data sets can represent polarized 129 Xe in gray matter, white matter, and cerebral blood (block 321 ).
- the image includes a plurality of voxels, the spectrum associated with each voxel provides a measure of perfusion for a number of (‘n”) compartments simultaneously.
- a curve can be fit to the dynamic data and a time constant determined (block 333 ).
- the image and/or dynamic data can be evaluated for at least one of ventilated cerebral blood flow, white matter perfusion, gray matter perfusion, demylenation, and hypoxia, or stroke (block 340 ).
- a therapeutic agent can be administered to the patient and the step of obtaining the dynamic data sets repeated (block 340 ) to evaluate the progression of disease, the efficacy of treatment and the like. Of course, the step can be repeated without administering a pharmaceutical or therapeutic agent to monitor disease, or progressive conditions.
- FIG. 12 illustrates yet another embodiment of operations.
- polarized 129 Xe is administered to the subject (block 400 ).
- At least one dynamic data set of signa strength over time of an NMR spectroscopic signal of the polarized 129 Xe in the body of the patient is obtained at at least one selected chemical shift frequency or resonance, the selected frequency corresponding to a membrane or lining in the body (block 420 ).
- the polarization of the 129 Xe can be destroyed locally prior to initiating the obtaining step (block 422 ).
- the dynamic data set can be evaluated to determine at least one of the thickness or adequacy of the membrane or lining (block 430 ).
- a curve can be fitted to the dynamic data and at least one of several characterizing parameters evaluated: including, for example, the time constant, selected amplitudes of the curve (such as peak or at t>> ⁇ ), or the slope associated with perfusion uptake of 129 Xe (block 433 ).
- a therapeutic agent can be administered and the operations described in blocks 420 and 430 repeated (block 440 ).
- a patient is positioned in an MRI unit and exposed to a magnetic field.
- the MRI unit typically includes a super-conducting magnet, gradient coils (with associated power supplies), an NMR coil (transmit/receive RF coil), and a RF amplifier for generating RF pulses set at predetermined frequencies.
- the MRI unit is set to operate in the gas-phase at about 17.6 MHz.
- the dissolved phase excitation frequency is shifted below the gas phase excitation frequency such as between about 196 to at least 200 ppm lower than the gas phase excitation frequency (corresponding to the chemical shift).
- the dissolved phase 129 Xe RF excitation frequency can be about 3.52 kHz lower than the associated gas-phase excitation frequency.
- the imaging method employs a 17.6 MHz gas phase excitation pulse and an associated dissolved phase excitation pulse of about 17.59648 MHz.
- the magnet field strength and excitation frequency can vary, as is well known to those of skill in the art depending on the target region/tissue or environment undergoing evaluation.
- the RF pulse(s) is transmitted to the patient to excite the nuclei of the polarized 129 Xe.
- the NMR coil is tuned to a selected frequency range and positioned adjacent the targeted imaging region to transmit the excitation pulses and to detect responses to the pulse sequence generated by the MRI unit.
- NMR coils for standard chest imaging can include a wrap-around coil with conductors positioned on both the front and back of the chest. Examples of acceptable coils known to those of skill in the art include a bird-cage configuration, a Helmholtz pair, a surface coil, and a solenoid coil (for permanent magnets). Other surface coils can be used for other imaging regions of the body (such as the head, torso, and the like).
- the patient can inhale a quantity of polarized 129 Xe gas into the pulmonary region (i.e., lungs and trachea). After inhalation, the patient can hold his or her breath for a predetermined time, such as 5-20 seconds. This can be described as a “breath-hold” delivery.
- suitable “single dose” quantities of polarized gases for breath-hold delivery include 0.25-0.5, 0.75, and 1.0-2.0 liters of gas.
- the dose at inhalation can contain gas with a suitable polarization level, typically so that the polarization at delivery is well above 5%, and preferably a polarization level above about 20%-50%.
- the MRI unit can deliver a suitable excitation pulse.
- the excitation pulse can be a large flip angle RF excitation pulse to a selected portion of the pulmonary vasculature.
- large flip angle means an angle that is greater than about 30 degrees, and typically greater than about 75 degrees, and more typically about 90 degrees.
- a 30-degree flip angle will generally yield about 50% as much signal as a 90-degree flip (45 degrees typically giving about 70% as much signal).
- the RF excitation can be selectively performed. “Selective excitation” is generated such that it excites only certain frequencies, i.e., that it excites substantially only the dissolved phase polarized gas.
- An exemplary delivery of a selective excitation pulse is via a “hard” pulse.
- “hard” pulse includes pulses where the RF is turned on for a short pulse time (“t pulse ”) and then shortly thereafter, indeed preferably substantially “instantly,” turned off. However, short pulse times can yield uncertainty in the associated frequency it generates.
- selective excitation is performed such that the pulse frequency is centered on the dissolved gas phase resonance desired (i.e., 17.59648 MHz) and has a pulse time, t pulse , such that the associated frequency is below the corresponding gas phase excitation frequency (i.e., 17.6 MHz).
- a large flip angle pulse is delivered to the target region so as to substantially destroy the incoming 129 Xe polarization or magnetization to set the “0” or monitoring start window for analyzing the transit time and/or polarized 129 Xe behavior/exchange dynamics.
- the selective excitation is timed such that it excites the entire pulmonary blood volume.
- the pulmonary blood volume includes the volume of blood that fills the blood passages associated with the circulatory system between and/or within the lungs and the heart (which can include the volume of blood or a portion of the volume of blood within the boundary lung tissue and/or heart).
- a large flip angle excitation of the dissolved phase 129 Xe in the pulmonary vasculature allows for the initialization of the “0” level to monitor the gas-exchange dynamics.
- “fresh” magnetization i.e., polarized 129 Xe
- U.S. patent application Ser. No. 09/271,476 and U.S. patent application Ser. No. 09/271,476 for descriptions of imaging methods using 129 Xe. The contents of these documents are hereby incorporated by reference as if recited in full herein.
- pulmonary and cardiac vasculature includes all of the blood vessels within the lungs and/or heart, the chambers of the heart, the passages between the chambers of the heart, as well as the blood vessels between the lungs and heart, and blood vessels between the lungs or heart and other tissues and/or organs.
- the pulmonary and cardiac vasculature includes, but is not limited to, the pulmonary veins and arteries and associated capillaries, the left and right atria of the heart, the left and right ventricles of the heart, the myocardium, the aorta and aortic arch, the coronary artery, the coronary arteries, the subclavian arteries, and the carotid arteries.
- This concentration can be expected to equilibrate in the venous side of the pulmonary vasculature just a few seconds after inhalation.
- the standard unit for concentration is an “amagat” which refers to 1 atmosphere of gas pressure at a temperature of 273K.
- amagat refers to 1 atmosphere of gas pressure at a temperature of 273K.
- V Xe volume of Xe into their lungs of volume
- an estimate of ⁇ for Xe in blood is that 8 ⁇ 0.15.
- a patient who inhales 1 L of Xe into his 6 L lung will yield a Xe density in the lungs of [Xe] L ⁇ 0.15 amagat, and correspondingly a Xe density in the pulmonary capillary beds of [Xe] P ⁇ 0.02 amagat.
- the dissolved polarized 129 Xe gas in the pulmonary capillary beds will saturate at approximately 1 ⁇ 6 the concentration of the lung gas.
- the present invention provides perfusion images that can be two (2) and three (3) dimensional multi-peak dissolved phase images of the perfusion in selected regions of the body such as the pulmonary vasculature or selected tissue in the brain ( FIG. 8B ) and the like.
- a patient who inhales 1 L of Xe into the lungs will yield about or dissolve into about 1 ⁇ 6 of that value of the xenon concentration (0.02 amagat) in the pulmonary vasculature and associated blood.
- the method uses frequency selective large angle (more preferably 90°) RF excitation pulses that substantially deplete the 129 Xe in the pulmonary blood but leave the hyperpolarized gas in the lungs substantially undisturbed to define the initial monitoring period during which dynamic NMR signal data is obtained.
- the repetition time interval between RF pulses (T R ) and the pulmonary blood flow rate (Q) can be used to determine the effective pulmonary volume (V eff ) containing (dissolved phase) hyperpolarized 129 Xe.
- V eff effective pulmonary volume
- t p the time it takes for the polarized 129 Xe to leave the pulmonary blood
- the signal strength is dependent on both the pulse interval (T R ) and the blood flow rate (Q).
- the slope “m” of polarized xenon in the pulmonary blood is directly proportional to the pulmonary blood flow rate (Q). Calibration of the blood flow rate is obtainable by evaluating the gas phase signal (“S L ”) in the lung, the signal having an associated small RF tipping angle (excitation angle) (“ ⁇ L ”).
- lung volume can be easily established to about 20% accuracy with techniques known to those of skill in the art.
- techniques with relatively improved accuracy such as but not limited to spirometry are used.
- the spectroscopic evaluation methods do not require a polarization calibration because the measurement can be “self-calibrating.” Stated differently, the polarization can be cancelled by comparing dissolved and gaseous xenon signal, both of which can be assumed to have substantially the same or identical polarization to the extent that T1 relaxation in the blood is negligible, which it is for short T R settings as discussed above.
- the present invention can be practiced to give a quantitative assessment of perfusion as will be appreciated by one of skill in the art.
- signal intensity can be followed over time as noted above. Examples of such quantitative relationships were developed for use with radioactive contrast agents with MR imaging and spectroscopy methods may be particularly suitable for dissolved phase 129 Xe analysis of blood vessels. See, generally, Lassen, Cerebral Transit of an Intravascular Tracer may Allow Measurement of regional Blood Volume but not Regional Blood Flow, 4 J. Cereb. Blood Flow and Metab. 633 (1984).
- inventive methods may be used for wide range of diagnostic and evaluative applications, as described herein.
- Other applications of the present invention include, but are not limited to: identification and assessment of the presence or absence and/or severity of cardiac ischemias and/or infarcts; localization and assessment of thrombi and plaques; determination of “therapeutic windows” for administering heparin, vasodilators, antihypertensive agents, calcium antagonists and the like, e.g., in reversible focal ischemia; monitoring of other induced vasodilator effects; detection and quantitative evaluation of the severity of ischemias; monitoring the vasodilatory or vasocontractory effects of a physiologically active substance; and monitoring surgically induced blood perfusion variations.
- the present invention may further be employed for: assessment of cerebral perfusion in following induced subarachnoid hemorrhage or in conditions marked by brain dysfunction, e.g., in connection with acute severe symptomatic hyponatremia; evaluation of new therapies, e.g., in the treatment of cerebral vasospasm (including but not limited to, anti-thrombolytic therapies, calcium channel blockers, anti-inflammatory therapies, angioplasty, and the like); assessment of the presence or absence and/or severity of ischemia in large tissue masses; assessment of the relationship between blood metabolites and cerebral perfusion in cerebral ischemia associated with acute liver failure, e.g., for the treatment of Alzheimer's disease; evaluation of new therapies for stroke, including but not limited to, t-PA, aspirin antiphospholipids, lupus anticoagulants, antiphospholipid antibodies, and the like; evaluation of risk factors for stroke, e.g., serum lipid levels; evaluation of induced brain hypothermia on cerebral perfusion during neurosurgery, e.g.
- hyperpolarized 129 Xe can be administered to a patient by inhalation or injection. If the administration modality is injection, 129 Xe can be suspended in a carrier fluid or injected directly such as in gaseous form. However, regardless of what tissue is of interest, if the 129 Xe is suspended in a carrier fluid, it is likely that the carrier fluid itself distorts the results of the spectra and/or substantially obscures a spectral peak of interest.
- the carrier fluid may also react with the target tissue (region of interest) and/or potentially produce compounds with molecules in or around the tissue of interest, which may thereby cause the chemical shift of hyperpolarized 129 Xe to differ from that which would be observed with merely the tissue of interest and hyperpolarized 129 Xe. Therefore, direct injection of gaseous 129 Xe or administration via inhalation may be particularly suitable for certain embodiments or applications.
- direct injection of gaseous 129 Xe see co-pending U.S. application Ser. No. Ser. No. 09/804,369, the contents of which are hereby incorporated by reference as if recited in full herein.
- the spectral peaks may be quantified by normalizing the spectral data.
- the term “normalizing” means to adjust the signal data of the spectral peak or peaks of interest to account for selected signal variables. This adjustment may include using the mathematic ratio of the values of certain peaks associated with selected known biomatter (RBC, plasma, etc) within the response spectrum to quantify the hyperpolarized gas signal in the region of interest.
- the adjustment may include using the polarization level (and/or quantity) of the administered gas measured at the time of delivery to obtain a base or reference spectrum to quantify the magnitude of the signal.
- the normalization can use relative data and/or absolute data.
- the ratio of the spectra for the blood to spectra of the brain tissue can be calculated.
- other known chemical shift peak locations can also be used to normalize the value of the spectra peak of interest.
- the absolute data can include data associated with the polarization level of the gas as it is delivered to the patient and/or the amount of gas administered thereto (to account for signal strength).
- a region-specific NMR coil can be positioned over the region of interest and to transmit a selected RF pulse sequence.
- the coil receives a FID signal.
- Localizing gradients can also be applied about the region of interest so as to localize the resonance region. For example, localizing gradients can be applied so that a desired region of interest is excited (either the left or right). In any event, the Fourier Transform of the acquired data is then calculated.
- the transformed signal data can be further processed which may include, but is not limited to, one or more of subtracting background noise, filtering undesirable signal data (such as those portions of the signal or spectra attributed to carrier liquids or deposits in non-target tissue or blood and the like), determining the frequency shift and size of the shift for any number of peaks within pre-determined ranges in the spectrum, and normalizing the data such as finding the ratios between magnitudes and/or areas of different spectral peaks within the response spectrum or accounting for polarization level and amount of polarized gas delivered to the subject.
- subtracting background noise filtering undesirable signal data (such as those portions of the signal or spectra attributed to carrier liquids or deposits in non-target tissue or blood and the like)
- determining the frequency shift and size of the shift for any number of peaks within pre-determined ranges in the spectrum and normalizing the data such as finding the ratios between magnitudes and/or areas of different spectral peaks within the response spectrum or accounting for polarization level and amount of polarized gas delivered to the subject.
- the present invention finds use for both pre-clinical animal studies, veterinary and medical applications.
- the present invention may be advantageously employed for diagnostic evaluation and/or treatment of subjects, in particular human subjects, because it may be safer (e.g., less toxic) than other methods known in the art (e.g., radioactive methods).
- the inventive methods may be more readily accepted because they avoid radioactivity or toxic levels of chemicals or other agents.
- Subjects according to the present invention can be any animal subject, and are preferably mammalian subjects (e.g., humans, canines, felines, bovines, caprines, ovines, equines, rodents, porcines, and/or lagomorphs), and more preferably are human subjects.
- These computer program instructions may also be stored in a computer-readable memory that can direct a computer or other programmable data processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable memory produce an article of manufacture including instruction means which implement the function specified in the flowchart and/or block diagram block or blocks.
- the computer program instructions may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide steps for implementing the functions specified in the flowchart and/or block diagram block or blocks.
- the present invention may be embodied as a method, data or signal processing system, or computer program product. Accordingly, the present invention may take the form of an entirely software embodiment or an embodiment combining software and hardware aspects. Furthermore, the present invention may take the form of a computer program product on a computer-usable storage medium having computer-usable program code means embodied in the medium. Any suitable computer readable medium may be utilized including hard disks, CD-ROMs, optical storage devices, or magnetic storage devices.
- the computer-usable or computer-readable medium may be, for example but not limited to, an electronic, magnetic, optical, electromagnetic, infrared, or semiconductor system, apparatus, device, or propagation medium. More specific examples (a non-exhaustive list) of the computer-readable medium would include the following: an electrical connection having one or more wires, a portable computer diskette, a random access memory (RAM), a read-only memory (ROM), an erasable programmable read-only memory (EPROM or Flash memory), an optical fiber, and a portable compact disc read-only memory (CD-ROM).
- RAM random access memory
- ROM read-only memory
- EPROM or Flash memory erasable programmable read-only memory
- CD-ROM portable compact disc read-only memory
- the computer-usable or computer-readable medium could even be paper or another suitable medium upon which the program is printed, as the program can be electronically captured, via, for instance, optical scanning of the paper or other medium, then compiled, interpreted or otherwise processed in a suitable manner if necessary, and then stored in a computer memory.
- Computer program code for carrying out operations of the present invention may be written in an object oriented programming language such as Java7, Smalltalk or C++. However, the computer program code for carrying out operations of the present invention may also be written in conventional procedural programming languages, such as the “C” programming language or even assembly language.
- LAN local area network
- WAN wide area network
- Internet Service Provider for example, AT&T, MCI, Sprint, EarthLink, MSN, GTE, etc.
- the flowcharts and block diagrams illustrate methods to obtain dynamic NMR signal data and analyze and evaluate the data to (a) quantify the thickness of physiologic barriers such as structures or environments including tissue, membrane, or linings; (b) quantify the width of lumens or channels; (c) evaluate the adequacy of physiologic function of certain systems or membranes; (d) identify disruptions or compromised integrity of the barriers, structures, lumens, or channels and/or to identify disorders associated therewith; and (e) to provide perfusion map of the brain based on a concurrent acquisition of dynamic data at multiple chemical shifts associated with the brain across a plurality of compartments of the brain according to embodiments of the present invention.
- each block in the flow charts or block diagrams represents a module, segment, or portion of code, which comprises one or more executable instructions for implementing the specified logical function(s).
- the functions noted in the blocks may occur out of the order noted in the figures. For example, two blocks shown in succession may in fact be executed substantially concurrently or the blocks may sometimes be executed in the reverse order, depending upon the functionality involved.
Abstract
In certain embodiments, methods of the present invention obtain NMR spectroscopy signal data that corresponds to the behavior of the polarized 129Xe at a selected site(s) in selected environments in vivo. The gas exchange signal data can be used to evaluate: (a) the thickness of a barrier, such as a membrane, lining, wall or width of a lumen; (b) the operational condition or function of a membrane, body system or portion thereof; (c) cerebral perfusion; and/or (c) the efficacy of a therapeutic treatment used to treat a diagnosed disorder, disease, or condition. Thus, the present invention provides methods for screening and/or diagnosing a disorder or disease, and/or methods for monitoring the efficacy of therapeutics administered to subject to treat a disorder or disease.
Description
- The present invention relates to magnetic resonance imaging (“MRI”) and MR spectroscopy using hyperpolarized noble gases. More particularly, the present invention relates to techniques to assess certain physiology, conditions, and/or functions of organs or body systems in vivo using polarized noble gases.
- Conventionally, MRI has been used to produce images by exciting the nuclei of hydrogen molecules (present in water protons) in the human body. However, it has recently been discovered that polarized noble gases can produce improved images of certain areas and regions of the body that have heretofore produced less than satisfactory images in this modality. Polarized Helium 3 (“3He”) and Xenon-129 (“129Xe”) have been found to be particularly suited for this purpose. See U.S. Pat. No. 5,545,396 to Albert et al., entitled “Magnetic Resonance Imaging Using Hyperpolarized Noble Gases”, the disclosure of which is hereby incorporated by reference herein as if recited in full herein.
- In order to obtain sufficient quantities of the polarized gases necessary for imaging, hyperpolarizers are used to produce and accumulate polarized noble gases. Hyperpolarizers artificially enhance the polarization of certain noble gas nuclei (such as 129Xe or 3He) over the natural or equilibrium levels, i.e., the Boltzmann polarization. Such an increase is desirable because it enhances and increases the Magnetic Resonance Imaging (“MRI”) signal intensity, thereby potentially allowing physicians to obtain better images of many tissues and organs in the body.
- Generally stated, in order to produce the hyperpolarized gas, the hyperpolarizer is configured such that the noble gas is blended with optically pumped alkali metal vapors such as rubidium (“Rb”). These optically pumped metal vapors collide with the nuclei of the noble gas and hyperpolarize the noble gas through a phenomenon known as “spin-exchange”. The “optical pumping” of the alkali metal vapor is produced by irradiating the alkali-metal vapor with circularly polarized light (typically provided by lasers) at the wavelength of the first principal resonance for the alkali metal (e.g., 795 nm for Rb). Generally described, the ground state atoms become excited, then subsequently decay back to the ground state. In the presence of non-zero nuclear spin noble gases, the alkali-metal vapor atoms can collide with the noble gas atoms in a manner in which the polarization of the valence electrons is transferred to the noble-gas nuclei through a mutual spin flip “spin-exchange”.
- After the spin-exchange has been completed, the hyperpolarized gas is separated from the alkali metal prior to introduction into a patient.
- Conventionally, gas-phase imaging has been possible using both 3He and 129Xe, and has been particularly useful in producing ventilation-driven images of the lungs, a region where proton images have produced signal voids. However, in contrast to gas phase imaging, dissolved phase imaging has proven to be problematic. Dissolved phase imaging uses the solubility characteristic of 129Xe in blood and lipid rich tissue. The gas phase is thus absorbed or “dissolved” into surrounding tissue or blood vessels and may allow perfusion imaging of the brain, lung, or other regions. Such images can potentially allow for the performance of non-invasive studies of the pulmonary vasculature to detect emboli and other circulatory system problems. Unfortunately, once the polarized gas has been dissolved (such as into the blood vessels), it has proven difficult to generate clinically useful images using the dissolved phase gas.
- For example, MRI images using gas-space-imaging techniques have been generated using hyperpolarized 129Xe gas. See Mugler III et al., MR Imaging and Spectroscopy Using Hyperpolarized 129 Xe gas: Preliminary Human Results, 37 Magnetic Resonance in Medicine, pp. 809-815 (1997). While good correlation is seen between the gas-space signal in the xenon images and the gas-space signal void in the proton images, the spectra associated with the dissolved phase signal components were significantly lower than the gas-phase signal.
- There remains a need to provide clinically useful methods for using polarized gas to perform in vivo evaluations of the body.
- In certain embodiments, methods of the present invention obtain dynamic NMR spectroscopy signal data that corresponds to the behavior of polarized 129Xe at a selected site(s) or environment in vivo. The signal data can be used to evaluate: (a) the physiology (tissue volume or thickness/width) of a membrane, organ, tissue, or other physiological structure or environment; (b) the operational condition or function of a membrane, body system, or portion thereof; (c) cerebral perfusion; and/or (c) the efficacy of a therapeutic treatment used to treat a diagnosed disorder, disease, or condition. Thus, the present invention provides methods for screening and/or diagnosing a disorder or disease, and/or methods for monitoring the efficacy of therapeutics administered to subject to treat a disorder or disease.
- Particular embodiments of the present invention use 129Xe as a tracer for oxygen. A curve can be best-fit to the dynamic data to represent the behavior of the polarized 129Xe at selected chemical shifts or frequencies. The curve can have various characterizing parameters including: an associated time constant, peak amplitude, amplitude at the time constant, slope of linear portions, and the like. These characterizing parameters can be used to evaluate the target of interest.
- For example, the curve can illustrate the transit time of polarized 129Xe in a target in the body. Delayed (longer) transit times may represent thicker tissue, or poor perfusion to help evaluate whether the subject may be hypoxic (in one or more areas such as in the pulmonary blood, the cardiac region, or in the brain). The polarized 129Xe can be used to determine whether low oxygen saturation is the result of poor ventilation, poor perfusion, and/or poor gas diffusing capacity across tissue or membranes. Such an analysis can be used to monitor therapeutic efficacy or disease progression.
- In certain embodiments, a dynamic data set of the signal strength of the 129Xe in selected tissue or environments over time can be generated and evaluated. Such information can be used in various manners such as to assess perfusion uptake, or the function of selected membranes, linings, and biosystems. The dynamic data set corresponds to the accrual, build up, or increase in signal strength over time of 129Xe at one or more chemical shift frequencies or ppm.
- Particular embodiments of the present invention are directed to minimally or non-invasive in vivo methods for evaluating the thickness or width of a physiological barrier such as a membrane, lining, lumen, channel, or wall in a subject using polarized 129Xe. The method includes: (a) delivering polarized 129Xe gas in vivo to a subject having a first environment, a physiological barrier having a thickness, and a second environment opposing the first environment such that the polarized 129Xe travels serially through the first environment, the barrier, and into the second environment, wherein the polarized 129Xe has an associated different NMR signal chemical shift frequency in the first and second environments and the barrier; (b) destroying the polarization of the 129Xe in the barrier and the second environment; (c) obtaining an NMR spectroscopic signal of the polarized gas in the subject at the second chemical shift to generate at least one dynamic data set of the NMR spectroscopic signal strength values over time representative of the behavior of the polarized 129Xe as it crosses the barrier and enters the second environment; (d) evaluating the polarized gas transit time of the polarized gas, the gas transit time corresponding to the time it takes the polarized gas to travel across the barrier and then enter the second environment, based on data provided by said obtaining step; and (e) determining the thickness or width of the barrier based on data provided by the calculating step.
- The method may further include (a) generating a signal strength versus time curve to fit the dynamic data; (b) identifying a time constant of the curve; and (c) evaluating the amplitude of the signal strength at a time along the curve corresponding to the time constant.
- In other embodiments, the operation or function of the membrane can be evaluated without determining the thickness of the membrane. In particular embodiments, the method can be used to measure membranes having a thickness in the range of about 1 micron to about 100 microns.
- Another embodiment is directed to in vivo methods for evaluating the blood brain barrier in a subject. The method comprises: (a) delivering polarized 129Xe in vivo to a subject such that it diffuses into the blood stream, across the blood brain membrane, and is taken up in tissue in the brain across the membrane, the polarized gas in the blood, membrane, and brain tissue having distinct corresponding polarized gas NMR chemical shift signal frequencies; (b) destroying the polarization of the polarized 129Xe in at least the brain tissue; (c) obtaining an NMR spectroscopic signal of the polarized gas in the subject over time at the brain tissue chemical shift frequency to generate at least one dynamic data set of the NMR spectroscopic signal strength values over time; (d) evaluating the dynamic data; and (e) assessing the blood brain barrier based on data provided by the obtaining and evaluating steps.
- Other embodiments of the present invention are directed at methods for monitoring gas exchange dynamics of 129Xe at or across the blood brain barrier to evaluate inflammatory disorders of the brain such as meningitis, encephalitis, and the like and/or to provide methods that can distinguish between certain disorders such as between meningitis and cerebritis by analyzing the gas exchange reaction at the blood barrier membrane. Still other embodiments are directed to measurement of organ perfusion by monitoring xenon transport in, to, or through, that organ.
- Still other embodiments are directed to methods of obtaining cerebral perfusion information. The method comprises: (a) administering polarized 129Xe to a subject in vivo; (b) concurrently obtaining a plurality dynamic data sets of NMR spectrographic signal strength of the polarized 129Xe in a compartment of the brain of the subject representative of perfusion in the brain, each dynamic data set corresponds to a different chemical shift frequency; (c) repeating step (b) for a plurality of different compartments across the brain; and (d) generating at least one perfusion image of the brain based on the data provided by the obtaining steps, wherein the image comprises a plurality of voxels associated therewith, and wherein each voxel corresponds to a measure of perfusion in the associated compartment in the brain.
- Other embodiments are directed to in vivo methods for evaluating at least one of the thickness of adequacy of function of a membrane or lining, comprising: (a) delivering polarized 129Xe in vivo to a subject such that the polarized 129Xe moves across the membrane or wall, the polarized gas in the membrane or wall having a corresponding polarized gas NMR chemical shift signal frequency; (b) obtaining an NMR spectroscopic signal of the polarized gas in the subject over time at the chemical shift frequency to generate at least one dynamic data set of the NMR spectroscopic signal strength values over time; and (c) evaluating at least one of (1) the adequacy of function of the membrane or lining and (2) the thickness of the membrane or lining based on the data provided by said obtaining step.
- Another embodiment of the present invention is directed to a computer program product for evaluating bioactivity, physiology, and/or perfusion in vivo. The computer program product includes computer readable storage medium having computer readable program code embodied in the medium, the computer-readable program code comprises: (a) computer readable program code that obtains an NMR spectroscopic signal of polarized 129Xe in the subject over time at at least one selected chemical shift frequency to generate at least one dynamic data set of the NMR spectroscopic signal strength over time; and (b) computer readable program code that analyzes the dynamic data set for at least one of: (a) quantifying the thickness of a physiologic barrier such as a tissue, membrane, or lining of interest (b) quantifying the width of a lumen or channel; (c) evaluating the adequacy of physiologic function of certain biosystems or membranes; (d) identify disruptions or compromised integrity of physiological barriers, structures, lumens, or channels and/or to identify disorders associated therewith; and (e) to provide a cerebral perfusion map of the brain based on a concurrent acquisition of dynamic data at multiple chemical shifts associated with the brain across a plurality of compartments of the brain.
- Further, the instant invention can use spectroscopic or MRI imaging techniques to obtain signal data corresponding to a quantity of dissolved polarized 129Xe before and after a physiologically active substance is administered to a human or animal body to evaluate the efficacy of the drug treatment.
- As will be appreciated by those of skill in the art in light of the present disclosure, embodiments of the present invention may include methods, systems and/or computer program products. The foregoing and other objects and aspects of the present invention are explained in detail herein.
-
FIG. 1 is a graph of 129Xe spectra showing the spectral signal of different chemical shifts of polarized xenon in blood and tissue. -
FIG. 2A is a schematic illustration of polarized gas distributed into two proximate regions in the body according to embodiments of the present invention. -
FIG. 2B is a simulated graph illustrating the chemical shifts associated with the two regions shown inFIG. 2A . -
FIG. 2C is a graph of signal strength as a function of time of the polarized gas in region two ofFIG. 2A according to embodiments of the present invention. -
FIG. 3A is a micrograph of lung tissue and alveoli structure. -
FIG. 3B is an enlarged micrograph of alveolar structure illustrating the capillary and alveolar air space and red blood cells. -
FIG. 4 is a graph illustrating the uptake of polarized 129Xe in blood over time according to embodiments of the present invention. -
FIG. 5A is a simulated graph of the signal of the 129Xe blood component over time according to embodiments of the present invention. The signal amplitude in blood is shown as one of the peaks of interest inFIG. 1 . -
FIG. 5B is a simulated graph of the signal of the 129Xe tissue component over time according to embodiments of the present invention. The signal amplitude in tissue is shown as one of the peaks of interest inFIG. 1 . -
FIG. 6 is a graph of the uptake of polarized 129Xe in blood over time. The graph illustrates three different curves fit to the dynamic data, each representing a different dynamic gas behavior which can be evaluated to ascertain information about the patient according to embodiments of the present invention. -
FIG. 7A is a polarized gas 129Xe measure of ventilation distribution MRI image of the lungs andFIG. 7B is a graph of the polarized 129Xe uptake over time; each can be generated based on a single-breath or ventilation administration of the polarized 129Xe according to embodiments of the present invention. -
FIG. 8B is an image of the brain wherein each voxel (3-D pixel) represents/measures the perfusion associated with a plurality of NMR frequencies simultaneously according to embodiments of the present invention.FIGS. 8A and 8C illustrate the perfusion signal amplitude data at a plurality of frequencies for the chemical shifts of brain tissue and/or cerebral blood flow shown inFIG. 8B . -
FIG. 9 is a flow chart illustrating one embodiment of operations for a method for spectroscopic analysis according to the present invention. -
FIG. 10 is a flow chart illustrating one embodiment of operations for a method for spectroscopic analysis according to the present invention. -
FIG. 11 is a flow chart illustrating one embodiment of operations for a method for spectroscopic analysis according to the present invention. -
FIG. 12 is a flow chart illustrating one embodiment of operations for a method for spectroscopic analysis according to the present invention. - The present invention will now be described more fully hereinafter with reference to the accompanying figures, in which embodiments of the invention are shown. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Like numbers refer to like elements throughout. In the figures, layers, regions or features may be exaggerated for clarity. Broken lines in the figures represent optional features or operations.
- As known to those of skill in the art, polarized gases are collected, frozen, thawed, and used in MRI and NMR spectroscopy applications. For ease of description, the term “frozen polarized gas” means that the polarized gas has been frozen into a solid state. The term “liquid polarized gas” means that the polarized gas has been or is being liquefied into a liquid state. Although each term includes the word “gas”, this word is used to name and descriptively track the gas that is produced via a hyperpolarizer to obtain a polarized “gas” product. Thus, as used herein, the term “gas” has been used in certain instances to descriptively indicate a hyperpolarized noble gas product and may be used with modifiers such as solid, frozen, dissolved, and liquid to describe the state or phase of that product. Also, for certain embodiments, the hyperpolarized gas is processed such that it is a pharmaceutical grade product suitable for in vivo delivery to a human subject. In particular embodiments, the 129Xe gas product is formulated to have less than about 10 ppb (parts per billion) alkali metal therein, and can have less than about 1 ppb.
- Various techniques have been employed to accumulate and capture polarized gases. For example, U.S. Pat. No. 5,642,625 to Cates et al. describes a high volume hyperpolarizer for spin-polarized noble gas, and U.S. Pat. No. 5,809,801 to Cates et al. describes a cryogenic accumulator for spin-polarized 129Xe. U.S. Pat. No. 6,079,213 to Driehuys et al., entitled “Methods of Collecting, Thawing, and Extending the Useful Life of Polarized Gases and Associated Apparatus”, describes an improved accumulator and collection and thaw methods. The disclosures of these documents are hereby incorporated by reference as if recited in full herein.
- As used herein, the terms “hyperpolarize,” “polarize,” and the like are used interchangeably and mean to artificially enhance the polarization of certain noble gas nuclei over the natural or equilibrium levels. Such an increase is desirable because it allows stronger imaging signals corresponding to better MRI images and spectroscopy signals of the gas in the body. As is known by those of skill in the art, hyperpolarization can be induced by spin-exchange with an optically pumped alkali-metal vapor or alternatively by metastability exchange. See Albert et al., U.S. Pat. No. 5,545,396.
- Referring now to
FIG. 1 , NMR signal strength spectrum data (obtained in vivo) of polarized 129Xe in the body of a subject is illustrated. The dissolved-phase spectra are shown on the left side of the figure (indicated by peaks at f1 and f2). The gas-phase spectra (on the right side of the figure at “0”) have a larger signal relative to the spectra of the 129Xe dissolved in blood or tissue. When a quantity of polarized 129Xe is inhaled into the lungs, a small fraction of this gas (roughly about 0.3% per/second) transits into the pulmonary blood. It is known that polarized 129Xe in the lung exhibits three distinct NMR resonances: 0 parts per million (“ppm”) is associated with gaseous 129Xe, 197 ppm is associated with 129Xe dissolved in lung tissue (f1), and 212 ppm is associated with 129Xe dissolved in blood (f2). Each of the signal strengths at these resonances (or others) can be tracked as a function of time. - Table 1 listed hereinbelow illustrates examples of NMR resonances of additional bio-substances. Signal strength for the selected resonances can be tracked as a function of time with at least about millisecond resolution. Other peaks at other locations, environments, tissues or membranes in the body may be selected in other embodiments.
- Generally stated, the present invention monitors the behavior of the polarized 129Xe in the body by obtaining the signal strength over time between or at certain regions of the body to ascertain certain physiologic, performance, or systemic function information. For example, referring now to
FIG. 2A , polarized 129Xe is administered to a subject such that it is present in proximate regions, i.e., region 1 (identified by the number 1), and region 2 (identified by the number 2). As shown, in certain embodiments,region 1 andregion 2 can be separated by abarrier 10 such as a wall, membrane, tissue or other structure. As shown inFIG. 2B , the polarized gas inregion 1 has a chemical shift which is distinct from the polarized gas intoregion 2. In certain embodiments, thebarrier 10 can also have a signal with its own chemical shift. - In operation, as shown by the arrows in
FIG. 2A , the polarized gas in region 1 (either in gaseous or dissolved state) can travel or diffuse to, and hence supply, the polarized gas inregion 2. As shown inFIG. 2C , the build-up of signal of the polarized gas inregion 2 can be dynamically monitored. The transit time can be described as the time it takes for the polarized gas to cross thebarrier 10 in sufficient quantities or amounts to yield a detectable signal and/or to approach a substantially steady state condition in signal strength therefrom. In particular embodiments, a curve or line can be statistically “best-fit” to the dynamic data or signal strength over time. The line or curve will have an associated time constant (τ) which can be used to represent the transit time of the gas through thebarrier 10. The curve or line will have other characterizing parameters which are measurable or representative of physiologic condition, structure, or function, as will be discussed more below. - In operation, the polarization, and hence the signal, in region 2 (and the membrane or barrier 10) can be destroyed (such as by transmitting a large RF excitation signal to that region) and then the signal in
region 2 can be monitored as the signal strength of the chemical shift spectra of the polarizedgas entering region 2 rebuilds from the ongoing supply of polarized gas delivered thereto during the analysis period. -
FIG. 2C illustrates that the dynamic data can be generated with sufficient resolution to be able to measure uptake with sufficient resolution to obtain data points of signal strength over time to define a slope or line shape corresponding to the dynamic behavior of the polarized 129Xe in the tissue, region, or barrier. For example, the dynamic data can be obtained so as to provide signal strength data for a time which is at least twice the time constant to allow for a sufficient number of data points to render a representative line or curve. The time constants typically range from about 0.25 ms to about 2.5 seconds. - In operation, in certain particular embodiments, a dynamic data set of NMR spectroscopic blood signal strength of polarized 129Xe in an environment of interest (such as blood) over time at at least one chemical peak or shift of interest can be obtained and evaluated to assess certain physiological parameters, structures, or function of the structure or body systems or portions thereof (nervous system, circulatory, respiratory, or cerebral). The parameters can include, but are not limited to, one or more of perfusion uptake, the function or integrity of a physiologic structure such as a membrane, lining, or wall, and/or the thickness of the barrier or structure, including the membrane, lining, wall or the width of a lumen (such as a capillary or other lumen), red blood cell, or a body cavity. Characterizing parameters provided by the dynamic data include the time it takes the polarized gas to travel through the barrier or a selected tissue or environment (i.e., the transit time which can be represented by a calculated time constant as noted above), the oxygen saturation level or measure of ventilated blood volume (as a measure of shunt) in the patient. The dynamic data set corresponds to the accrual, build up, or increase in signal strength of a particular signal or signals with an associated chemical shift (such as in the pulmonary blood, the cerebral blood, or alveolar tissue), over time.
-
FIG. 3A is a micrograph of lung tissue or alveolar structure.FIG. 3B is enlarged (20×) compared to the scale shown inFIG. 3A and illustrates alveolar structure including the alveolar epithelium (Ep), the interstitium (Ei), the capillary endothelium (En), a capillary (C) and red blood cell (R) and alveolar air space (A). The present invention provides methods for evaluating gas transit behavior across lung tissue, and/or across the alveolar-capillary membrane into the pulmonary blood. In certain embodiments, this information can be used to evaluate chronic heart failure (“CHF”) because CHF typically disturbs the alveolar-capillary membrane and increases the resistance to polarized gas transfer as the gas attempts to travel toward the pulmonary blood (into the red blood cells). Elevation of the capillary pressure can increase the capillary permeability to water and ions and disrupt local regulatory mechanisms for gas exchange, leading to thickening of the alveolar-capillary interstitium, and/or to a decrease in membrane conductance and subsequent impairment of diffusion capacity. Monitoring of the transit time and/or behavior of 129Xe acting as a tracer across a membrane in resting conditions and during (incremental) actual or simulated exercise (and/or after administration of a pharmaceutical product or therapeutic agent) can be performed so as to measure the function of the alveolar-capillary membrane. Other physiology or structures, membranes, or other barriers and associated peaks and regions can be monitored for other conditions as noted above. -
FIG. 5A illustrates the signal strength of the 129Xe in blood (f2) over time andFIG. 5B illustrates the signal strength of the 129Xe in tissue (f1) over time. To obtain the curve or line shape representing the gas exchange or diffusion process in the body at a selected frequency or shift of interest, a series of increasingly longer pulses are transmitted to generate the response signal. A plurality of different dynamic data sets, each at different discrete frequencies or chemical shifts can be obtained concurrently. - To generate the dynamic data set of the 129Xe in the body, polarized 129Xe is administered to the subject or patient. Then the polarization of the polarized 129Xe can be destroyed in a selected in vivo environment, structure, or physiology and then allowed to rebuild. For example, gaseous polarized 129Xe can be inhaled into the lungs and then the 129Xe can diffuse to, and hence supply, the polarized 129Xe into the membrane (as it diffuses serially across Ep, Ei, and then En) and into the capillary and the pulmonary blood.
- As shown in
FIG. 4 , the build up of signal of the polarized 129Xe in a selected environment can be dynamically monitored to determine a time constant “τ” associated with transit time of the polarized 129Xe as it diffuses across the environment of interest (such as a lining, wall, or membrane). - In operation, in certain embodiments, to measure the time constant and/or obtain dynamic data, the polarization, and hence the signal, in the barrier (which, for the alveolar-capillary membrane, can include the alveolar epithelium, the interstitium, and the capillary endothelium) and in the proximate blood in the capillary/red blood cell(s) can be destroyed by transmitting a large angle RF excitation pulse thereto to define t=0 (defined as the time after the polarization is destroyed). Then NMR signal strength data of the polarized 129Xe is collected for a first time period. The signal strength of the chemical shift spectra of the polarized gas entering the blood increases over time as it rebuilds from “0” from the ongoing supply of polarized gas delivered from the lungs during the analysis period.
- Then the polarization is destroyed again and a second data collection is commenced by transmitting a second excitation pulse that is initiated at a second time (delayed relative to the first excitation to obtain data associated with the polarized 129Xe at a period that is later in time from the first excitation), such as at t=40 ms. Thus, to generate the line or curve (at least electronically) associated with the dynamic data set, the polarization is destroyed a plurality of times and then a series of incrementally spaced excitation pulses are transmitted to generate a response curve which maps the 129Xe behavior in vivo with at least about millisecond resolution. Stated differently, the polarization is destroyed each time and then the response data is collected at successively longer times to collect the signal data at the desired times in the analysis period. The NMR data can be collected using decremented pulse intervals (starting with the longest interval and moving to the shortest) or other sequences as desired. The data can be collected and the response curve of the 129Xe can be generated using curve fit using statistical analysis techniques well known to those of skill in the art. Other peaks at other locations, environments, tissues or membranes in the body may be selected in other embodiments and similarly evaluated for function.
-
FIGS. 5A and 5B illustrate that the dynamic data can be generated with sufficient resolution to measure uptake with sufficient resolution to define a line shape corresponding to the uptake of the 129Xe. To obtain sufficient data points to generate the time constant “τ”, the signal data can be collected for times that are at least two times that of the time constant. Thus, for time constants of 60 ms, data can be collected for at least about 120 ms. In certain embodiments, the time constant “τ” can be used to determine the thickness or width of the barrier. - Other embodiments of the invention assess or evaluate other conditions of other membranes or walls associated with lumens or natural body cavities that may be impaired in integrity or function. For example, the glomerular capillary membrane can be evaluated by administering polarized 129Xe to assess for any disruptions, apertures, permeability and flow rate across this membrane to give a quantitative assessment in health and disease. One result may be to record glomerular filtration rate and this could be given globally or for each individual kidney. This is useful in many clinical situations, e.g., measuring GFR prior to chemotherapy administration. In disorders such as the glomerulonephritidtis, the disease affects the structure and function of the membrane so the methods of the present invention can be used to monitor disease progression and effect of therapy. The disorders involved here may be acute and chronic renal failure, nephrotic syndrome, glomerulonephritis and other renal diseases. Similarly, the proximal or distal renal tubules may be evaluated using polarized 129Xe.
- In still other embodiments, the function of the large and/or small bowel wall can be evaluated. A quantitative assessment of bowel membrane integrity and function may be useful in a variety of gastroenterological diseases. In other embodiments, the placental membrane may be evaluated. The polarized 129Xe may be administered to the mother via inhalation or injection proximate to the placental membrane itself. A minimally or non-invasive method of assessing placental integrity and function other using 129Xe can provide additional information over conventional techniques (such as to observe the consequences of poor function by measuring fetal growth). Such a method of giving quantitative placental function may be a useful clinical tool in obstetrics.
- In alterative embodiments, the blood brain barrier can be evaluated so as to quantify or evaluate the integrity and function of this barrier or conditions associated therewith. The evaluation of the blood brain barrier can be to evaluate thickness or function or to assess for inflammatory disorders of the brain such as meningitis, encephalitis, and the like and/or to provide methods that can distinguish between certain disorders such as between meningitis and cerebritis by analyzing the gas exchange reaction at the blood barrier membrane. Other embodiments include assessing blood cell physiology or function defects or abnormalities (such as evaluating the presence or degree of sickle cell anemia).
- As shown in
FIG. 5A , in certain embodiments, after inhalation of hyperpolarized 129Xe, its uptake into a barrier, blood, or tissue can be measured as a function of time. The initial build-up rate (after the polarization is substantially destroyed in the membrane and the blood) of the xenon/blood or xenon/tissue signal is sensitive to barrier thickness. The spectroscopic signal of the xenon/blood or xenon/tissue can be used to quantify the thickness and/or the degree of edema or the function or thickness of the barrier associated with various conditions. The quantified or estimated thickness of the barrier membrane and/or the initial data associated with the gas exchange during the initial build up can also be used to evaluate other conditions as noted above. - In other embodiments, the response or behavior of the 129Xe during other portions of the analysis period can be used to evaluate ventilation/perfusion ratios. For example, the curve or line shown can be broken down into at least three characterizing parameter: the slope “m” corresponding to the linear rise in the signal after the initial portion of the signal, the time constant “τ” associated with the initial portion of the signal, and the amplitude defined by a steady state amplitude of the signal deconvoluted from the data representing the signal at the t>> than the calculated time constant “τ”. In particular embodiments, the amplitude of the signal that is 37% greater than the amplitude of the signal at the time=τ can be used to represent oxygen saturation of ventilated blood. The slope “m” can be used as a measure of global xenon uptake (as a tracer for oxygen) in the blood. The slope of this curve (“m”) may yield information about global blood flow to the ventilated portion of the lung and, hence, may be a predictor of shunt or cardiac output. Similarly, the amplitude of the 129Xe spectroscopic signal defined in relationship to the time constant can be used as a measure of oxygen saturation (ventilated blood volume). The time constant “τ” can also be used to evaluate or determine the thickness, function, or physiology of the barrier or membrane.
- In other embodiments, as shown in
FIG. 5B the NMR signal of 129Xe in tissue can also be monitored to evaluate tissue volume (corresponding to the peak amplitude of the curve associated therewith) while the time constant “τ” associated with the signal in tissue can be used as a measure of thickness. In certain embodiments the measured thickness can range from about 1 um-100 um. - The NMR signals and associated evaluations and measurements can be performed while the subject is substantially at rest and/or when the subject or patient is exposed to stress such as while exercising (or exposed to artificial stimulus elevating the heart beat rate and/or emulating other cardiopulmonary conditions).
- In addition, in certain embodiments, the dynamic data provided by the polarized 129Xe an be used to monitor a therapy administered to the subject for efficacy or for drug development processes where a new drug or use is undergoing evaluation during clinical or pre-clinical trials.
-
FIGS. 5A and 5B illustrate simulated signal strength (peak area) in % over successively longer incrementally increasing inter-pulse delay times. The xenon transit time into the monitored frequency shift occurs at the initial portion of the curve. - Measurement of the xenon/blood resonance signal (S) or the xenon/tissue resonance (or other environment of interest) as a function of time (“S(t))” can be expressed by the following mathematical relationship:
S(t)=S 0(1−e −t/τ). Equation (1)
Where “τ” is the time constant for polarized 129Xe associated with the uptake and/or dissolved gas-exchange transit time, and “S” is the signal strength of the polarized 129Xe at the selected frequency (or in the bio-environment or bio-structure of interest). These time constants have been measured in dogs to be at about 61 ms and 70 ms for the tissue and blood compartments, respectively. See Ruppert et al., NMR of Hyperpolarized 129 Xe in the Canine Chest: Spectral Dynamics During a Breath-Hold, 13 NMR in Biomedicine, p. 633-641 (2000). The time constants are representative of the amount of time it takes xenon to diffuse across the alveolar membrane and into the red blood cells. The diffusion constant of xenon in water is about 2×10−5 cm2/s. See Wolber et al., Measuring Diffusion of Xenon in solution with hyperpolarized 129Xe NMR, 296 Chemical Physics Letters, p. 391-396, (Nov. 6, 1998). The mean square distance traveled by a randomly diffusing gas can be approximated as described by Equation (2).
Z2=2Dt. Equation (2)
Where “Z2” is the mean square distance, “D” is the diffusion coefficient constant and “t” is the time it takes the gas to diffuse through the membrane. Thus, from the two transit times measured above, mean thickness or diffusion distances of about 15.6 μm and about 16.7 μm can be calculated. It is noted that these curves are taken from the entire lung and include regions where tissue is thicker or thinner. Alternative pulse sequences can be used to identify the uptake in the first few milliseconds (the transmit times are typically under about 100 ms) corresponding to transit times across the thinnest membranes. At the onset of certain diseases, the mean transit time can become longer (or shorter). Because diffusion time is proportional to the square of the tissue thickness, the transit time will be sensitive for quantifying wall thickness and/or thickening (or thinning as the case may be). -
FIG. 6 illustrates graphs of curves having three different time constants for the polarized 129Xe signal in blood illustrating the cardiopulmonary functional change that may be representative of heart failure or other disorders, diseases, or conditions. The time constant can be calculated byEquation 1 and is typically defined at when the signal is at about 63% of its ultimate value. As shown, the time constant for each of the curves varies in a quantifiable manner. The longer time constants (i.e., τ=150 and 300 ms) correspond to thicker alveolar-capillary membranes. In certain diseases or conditions, the alveolar membrane can thicken in response to hypertension or other conditions. As the condition deteriorates, the transit time or time constant “τ” increases (shown as going from 70 ms to 300 ms) corresponding to the thickening of the alveolar membranes in response to hypertension and the like (reducing oxygen diffusing capability). Many therapeutic regimens attempt to change physiology of certain regions, organs, or structures of the body (such as to thin the alveolar membranes) and the present invention can assess whether this objective has been achieved by evaluating the time constant τ and/or other 129Xe signal parameter. Monitoring such a progression or behavior to confirm that the therapy is effective of that the condition is not deteriorating may provide important clinical information. - The signal strength of the dissolved phase polarized xenon signal intensity versus repetition time can have an associated slope “m” which is a function of the signal and the pulse repetition (dSp/dTR). In operation, a large flip angle pulse (preferably a flip angle of about 90 degrees) can be transmitted to the blood; this destroys all the magnetization in the xenon and, thus, the signal of the dissolved polarized xenon in the blood. Subsequently, after the excitation pulse, additional polarized 129Xe is taken-up in the blood (replenished) over time until a substantially steady state level is reached: the more polarized xenon in the blood, the larger or stronger the associated signal. This increase in the dissolved phase xenon signal over time (after the initial transit time across the barrier) can be mathematically represented by the slope of the line (dSp/dTR). The slope (after an initial gas blood barrier crossing period) can be directly proportional to blood flow rate (Q) in the bloodstream.
- In order to determine the slope of the line associated with the signal of the dissolved phase xenon in the blood over time, the data acquisition can obtain several data points such as three-ten temporally separate data points within the first 60 ms to establish the time constant associated with the curve fit of the signal shape/129Xe behavior at the peak(s) of interest. In certain embodiments, it will take longer for blood to uptake polarized xenon where there is low blood flow in ventilated regions in the lung and a shallower blood signal slope may be indicated (representing a low blood flow rate in ventilated regions of the lung or other region).
- In certain embodiments, the slope data of the dissolved phase polarized 129Xe in tissue and/or blood versus can be adjusted by comparing it to the gas phase signal in the lung (SL). This gas phase signal (SL) is acquired from an excitation signal with a known flip angle ∀L (the polarized gas is conveniently available in the lung space). Thus, the present invention can use a mathematical relationship between the dissolved phase polarized xenon signal in the blood or tissue with the xenon signal in the gaseous phase in the lung to establish a quantitative measure of signal.
- In particular embodiments, a lung volume (VL) is measured by conventional means before or after the MR procedures, or by assuming an average or normalized lung volume for a particular patient size or age. After a short initial time, the slope of the curve corresponds to the blood flow rate in the blood stream.
- In summary, according to certain embodiments of the present invention, there are several quantifiable parameters that can be derived from the 129Xe uptake spectra: Speak (tissue), τ(tissue), Speak(blood), τ(blood), and slope of the linear uptake portion of the xenon/blood resonance. These uptake spectra may be performed on a regional basis in the lung. This dynamic signal data can be obtained with millisecond or better resolution. In certain embodiments, the alveolar transit time, oxygen saturation level, global perfusion, tissue volume and ejection fraction can be evaluated to identify any abnormalities or alterations in physiology or function.
- Generally stated, the ventilated blood flows to the heart to the left atrium to the left ventricle and pumped to body through the (arch of) aorta. The blood is forced or ejected from the heart in pulsatile flow corresponding to the pumping action thereof. The pulsatile flow behavior of the blood ejected from the aorta can be monitored to evaluate or map the ejection fraction. Gradient-tagged RF excitation pulses can be used to look at the signal of the 129Xe in the blood as it exits the aorta or left ventricle (or region proximate thereto). This targeted region can be monitored to obtain the signal strength of the 129Xe in this ejected blood over time, the signal will increase and decrease corresponding to the cardiac cycle and the signal can be evaluated to assess how much of the polarized blood is pumped out of the left ventricle or aorta in each pumping cycle. This ejection fraction can be compared to the subject's own previous evaluation or based on a statistical population average (by gender and/or age which can be generally stated to be an average of about 60%) to asses whether there is an abnormality. Thus, for example, if 200 ml of ventilated (polarized) blood is pumped into the heart and 100 ml is ejected, the ejection fraction may be identified as 50% (lower than average). Thus, in certain embodiments, the dynamic gas exchange data of signal over time in one, two, or more different environments, regions, or tissues (such as tissue and blood) can provide information on ventilation, perfusion, and ejection fraction, as noted above.
- In addition, as shown in
FIGS. 7A and 7B , in certain embodiments, there may be enough magnetization or polarization associated with the 129Xe in vivo to perform a polarized 129Xe ventilation or 1H MRI ventilation image in the same breath-hold period, typically of about 10 seconds. The combination image/scan with the spectroscopic analysis can provide additional information on the state of the cardiopulmonary system. In certain embodiments, the test can be carried out in an MRI magnet with a dual-tuned 129Xe/1H coil to allow conventional or standard imaging to be performed to yield anatomical information in the same MR imaging/spectroscopy session. It is noted that the image shown is based on polarized 3He because it is readily accessible, but it is anticipated that a similar resolution ventilation image can be generated using polarized 129Xe. - The
barrier 10 can be a wall, membrane, lining, tissue, red blood cell, or other structure, fluid, or environment in the body. In certain embodiments the gas-exchange dynamics of membranes can be evaluated using the dynamic data sets of polarized 129Xe. - Particular embodiments of the present invention are directed to methods of evaluating the dynamic behavior of the polarized 129Xe in a target region in the body to evaluate the cerebral perfusion of a subject, or other structures or membranes for dysfunctions. The polarized 129Xe can be used to determine one or more of whether low oxygen saturation is the result of poor ventilation, poor perfusion, and/or poor gas diffusing capacity across the alveolar membrane. Such an analysis can be used to diagnose chronic heart failure, to differentiate uncertain aetiology of breathlessness such as to identify cardiac or respiratory origin, to determine the adequacy of the alveolar-capillary unit, and to monitor therapeutic efficacy of treatments on those conditions.
- For example, upon presentation to respiratory physicians, many patients exhibit a shortness of breath of uncertain aetiology. Thus, in certain embodiments, the present invention allows for evaluations of the adequacy of the alveolar-capillary unit using polarized 129Xe in a manner that can be useful to allow proper diagnosis and treatment. Potential clinical indications which can be assessed by methods of the present invention include, but are not limited to, the presence and/or extent of emphysema, the presence and/or extent of alveolitis (and follow-up monitoring for same), to differentiate pure airway conditions from conditions which affect the alveolar airspaces, the diagnosis of alveolar hemorrhagic conditions, and the diagnosis of radiation pneumonitis.
-
FIGS. 8A-8C illustrate another exemplary embodiment, where regional cerebral perfusion can be evaluated.FIGS. 8A and 8C are spectra of the polarized xenon at different locations (compartments) in the brain. The various peaks in the spectroscopic spectrums illustrate that a plurality of dynamic data sets (one for each of two, or more peaks shown by the three arrows pointed at certain peak positions) may be concurrently obtained at each compartment. This can be repeated to provide a cerebral perfusion map. That is, a simultaneous presentation of multiple peaks associated with perfusion in the brain. The peaks may correspond to gray matter, white matter, and the like. The perfusion data provided by the dynamic data can be used to construct a perfusion image of the brain where each voxel measures or quantifies a perfusion of a number of compartments simultaneously with moderate resolution (shown as about 5 mm or 1 cm3). Such information can evaluate regional cerebral blood flow, white matter perfusion, gray matter perfusion, demylenation, and hypoxia or stroke. The cerebral perfusion image can combine the signal strength information of the multiple data sets or can be used separately to provide three different perfusion maps of the brain based on data obtained concurrently. -
FIG. 9 is a flow chart of operations according to certain embodiments of the present invention. As shown, polarized 129Xe is administered to a patient in vivo (block 100). At least one dynamic data set of signal strength over time of an NMR spectrographic signal of the polarized 129Xe in the body of the patient is obtained at at least one selected chemical shift frequency (resonance) (block 120). A plurality of concurrent dynamic data sets can be obtained for different resonances, as desired. The polarization of the 129Xe can be destroyed locally prior to the obtaining the dynamic data (block 122). The dynamic data can be evaluated to determine the thickness or width of a physiologic barrier such as a membrane, wall, or lumen (block 130). A curve of signal strength over time can be generated to statistically “best-fit” the dynamic data (block 133) and a time constant associated therewith can be determined (block 133). A therapeutic agent can be administered and the operations described inblocks -
FIG. 10 illustrates the operations of another embodiment of the present invention. As before, polarized 129Xe is administered to a patient in vivo (block 200). At least one dynamic data set of an NMR spectrographic signal of the polarized 129Xe in the body of the patient at at least one selected chemical shift frequency over time is obtained. The chemical shift frequency or resonance can be selected to correspond to brain tissue (such as gray matter or white matter). As before, the polarization of the 129Xe can be destroyed locally proximate the brain tissue prior to initiating the obtaining step (block 222). The dynamic data can be evaluated to determine at least one of the thickness or adequacy of the function of the blood brain barrier function (block 230). A curve can be generated to fit the dynamic data and certain characterizing parameters can be evaluated. For example, the time constant, selected amplitude(s) of the curve, the area under the curve, the slope associated with the perfusion uptake into the brain (white or gray matter or cerebral blood) (block 233). A therapeutic agent can be administered to the patient and the operations recited inblocks - In certain embodiments, polarized 129Xe is delivered to the brain via the blood stream and crosses the blood brain barrier to diffuse into brain tissue. Thus, the polarization can be destroyed and then the NMR signal strength over time associated with uptake of 129Xe in one or more brain tissue components can be monitored to assess blood brain barrier function and/or thickness or physiology.
-
FIG. 11 is a flow diagram of operations of yet another embodiment. As before, polarized 129Xe is administered to the subject or patient (block 300). Then a plurality of dynamic data sets are obtained concurrently, each of the dynamic data sets being representative of a different chemical shift frequency of an NMR spectrographic signal of the polarized 129Xe in the brain. As before the polarization of the 129Xe can be destroyed prior to commencing the obtaining operation (block 322). At least one cerebral perfusion image can be generated mapping the perfusion in the brain associated with a plurality of different brain constituents (block 330). The data sets can represent polarized 129Xe in gray matter, white matter, and cerebral blood (block 321). The image includes a plurality of voxels, the spectrum associated with each voxel provides a measure of perfusion for a number of (‘n”) compartments simultaneously. As before a curve can be fit to the dynamic data and a time constant determined (block 333). The image and/or dynamic data can be evaluated for at least one of ventilated cerebral blood flow, white matter perfusion, gray matter perfusion, demylenation, and hypoxia, or stroke (block 340). A therapeutic agent can be administered to the patient and the step of obtaining the dynamic data sets repeated (block 340) to evaluate the progression of disease, the efficacy of treatment and the like. Of course, the step can be repeated without administering a pharmaceutical or therapeutic agent to monitor disease, or progressive conditions. -
FIG. 12 illustrates yet another embodiment of operations. Again, polarized 129Xe is administered to the subject (block 400). At least one dynamic data set of signa strength over time of an NMR spectroscopic signal of the polarized 129Xe in the body of the patient is obtained at at least one selected chemical shift frequency or resonance, the selected frequency corresponding to a membrane or lining in the body (block 420). Also, as before, the polarization of the 129Xe can be destroyed locally prior to initiating the obtaining step (block 422). The dynamic data set can be evaluated to determine at least one of the thickness or adequacy of the membrane or lining (block 430). Again a curve can be fitted to the dynamic data and at least one of several characterizing parameters evaluated: including, for example, the time constant, selected amplitudes of the curve (such as peak or at t>>τ), or the slope associated with perfusion uptake of 129Xe (block 433). A therapeutic agent can be administered and the operations described inblocks - Generally stated, in operation, a patient is positioned in an MRI unit and exposed to a magnetic field. The MRI unit typically includes a super-conducting magnet, gradient coils (with associated power supplies), an NMR coil (transmit/receive RF coil), and a RF amplifier for generating RF pulses set at predetermined frequencies. For 129Xe imaging at 1.5 T field strength, the MRI unit is set to operate in the gas-phase at about 17.6 MHz. The dissolved phase excitation frequency is shifted below the gas phase excitation frequency such as between about 196 to at least 200 ppm lower than the gas phase excitation frequency (corresponding to the chemical shift). Thus, the dissolved phase 129Xe RF excitation frequency can be about 3.52 kHz lower than the associated gas-phase excitation frequency. In other embodiments, the imaging method employs a 17.6 MHz gas phase excitation pulse and an associated dissolved phase excitation pulse of about 17.59648 MHz. Of course, the magnet field strength and excitation frequency can vary, as is well known to those of skill in the art depending on the target region/tissue or environment undergoing evaluation.
- In any event, the RF pulse(s) is transmitted to the patient to excite the nuclei of the polarized 129Xe. The NMR coil is tuned to a selected frequency range and positioned adjacent the targeted imaging region to transmit the excitation pulses and to detect responses to the pulse sequence generated by the MRI unit. NMR coils for standard chest imaging can include a wrap-around coil with conductors positioned on both the front and back of the chest. Examples of acceptable coils known to those of skill in the art include a bird-cage configuration, a Helmholtz pair, a surface coil, and a solenoid coil (for permanent magnets). Other surface coils can be used for other imaging regions of the body (such as the head, torso, and the like).
- In certain embodiments, the patient can inhale a quantity of polarized 129Xe gas into the pulmonary region (i.e., lungs and trachea). After inhalation, the patient can hold his or her breath for a predetermined time, such as 5-20 seconds. This can be described as a “breath-hold” delivery. Examples of suitable “single dose” quantities of polarized gases for breath-hold delivery include 0.25-0.5, 0.75, and 1.0-2.0 liters of gas. The dose at inhalation can contain gas with a suitable polarization level, typically so that the polarization at delivery is well above 5%, and preferably a polarization level above about 20%-50%.
- In overview, according to embodiments of the instant invention, shortly after inhalation of a suitable amount of hyperpolarized 129Xe gas (or gas mixture), the MRI unit can deliver a suitable excitation pulse. In particular embodiments, the excitation pulse can be a large flip angle RF excitation pulse to a selected portion of the pulmonary vasculature. As used herein, “large flip angle” means an angle that is greater than about 30 degrees, and typically greater than about 75 degrees, and more typically about 90 degrees. A 30-degree flip angle will generally yield about 50% as much signal as a 90-degree flip (45 degrees typically giving about 70% as much signal).
- The RF excitation can be selectively performed. “Selective excitation” is generated such that it excites only certain frequencies, i.e., that it excites substantially only the dissolved phase polarized gas. An exemplary delivery of a selective excitation pulse is via a “hard” pulse. As used herein, “hard” pulse includes pulses where the RF is turned on for a short pulse time (“tpulse”) and then shortly thereafter, indeed preferably substantially “instantly,” turned off. However, short pulse times can yield uncertainty in the associated frequency it generates. In certain embodiments, selective excitation is performed such that the pulse frequency is centered on the dissolved gas phase resonance desired (i.e., 17.59648 MHz) and has a pulse time, tpulse, such that the associated frequency is below the corresponding gas phase excitation frequency (i.e., 17.6 MHz). For example, one frequency spectrum of a square excitation pulse having a time tpulse and which is centered on a frequency (“fo”) can be described by the equation:
sin(a(f−fo)/a(f−fo)), where a=3.1416*t pulse. (Equation 3) - Therefore, the pulse time tpulse is preferably set so that the sin(a(f−fo))=0 for the gas phase component. Stated differently, the pulse time tpulse is determined according to the relationship tpulse=1/(f−fo). In one embodiment, for a 1.5 T magnetic field strength, f−fo equals 3.52 kHz and tpulse is about 284 μseconds (10−6). Of course, as will be recognized by those of skill in the art, alternative approaches can also be used, such as, but not limited to, sine pulses, gaussian pulses, and the like.
- In certain embodiments, a large flip angle pulse is delivered to the target region so as to substantially destroy the incoming 129Xe polarization or magnetization to set the “0” or monitoring start window for analyzing the transit time and/or polarized 129Xe behavior/exchange dynamics. Thereafter, in certain embodiments, the selective excitation is timed such that it excites the entire pulmonary blood volume. The pulmonary blood volume includes the volume of blood that fills the blood passages associated with the circulatory system between and/or within the lungs and the heart (which can include the volume of blood or a portion of the volume of blood within the boundary lung tissue and/or heart). Advantageously, unlike imaging the gas-phase 129Xe in the lung where conventionally small flip angles are used to avoid destroying the available magnetization, a large flip angle excitation of the dissolved phase 129Xe in the pulmonary vasculature allows for the initialization of the “0” level to monitor the gas-exchange dynamics. Further, according to the certain embodiments using inhalation delivery of the 129Xe, “fresh” magnetization (i.e., polarized 129Xe) is substantially continuously flowing in from the capillary beds during the procedure. See co-assigned and co-pending U.S. patent application Ser. No. 09/271,476 and U.S. patent application Ser. No. 09/271,476 for descriptions of imaging methods using 129Xe. The contents of these documents are hereby incorporated by reference as if recited in full herein.
- The term “pulmonary and cardiac vasculature” as used herein includes all of the blood vessels within the lungs and/or heart, the chambers of the heart, the passages between the chambers of the heart, as well as the blood vessels between the lungs and heart, and blood vessels between the lungs or heart and other tissues and/or organs. The pulmonary and cardiac vasculature includes, but is not limited to, the pulmonary veins and arteries and associated capillaries, the left and right atria of the heart, the left and right ventricles of the heart, the myocardium, the aorta and aortic arch, the coronary artery, the coronary arteries, the subclavian arteries, and the carotid arteries.
- Almost immediately upon inhalation of hyperpolarized 129Xe into the lungs, Xe begins to dissolve into the pulmonary blood stream (typically in under about 100 ms). The concentration of Xe in the pulmonary capillary beds (“[Xe]P”) can be assumed to equilibrate after an initial gas transit time (as the gas travels across the alveolar-capillary membrane) with the concentration of Xe in the lung gas spaces (“[Xe]L”). Thus, the relationship can be stated as:
[Xe]P=8[Xe]L, (Equation 4)
where “8” is the Xe blood/gas partition coefficient or blood solubility. This concentration can be expected to equilibrate in the venous side of the pulmonary vasculature just a few seconds after inhalation. The standard unit for concentration is an “amagat” which refers to 1 atmosphere of gas pressure at a temperature of 273K. For humans whose lungs contain one atmosphere of gas and whose temperature is about 310K, all gas densities should be scaled down by a factor of about A=0.88 amagat per atmosphere. For a patient inhaling a volume (“VXe”) of Xe into their lungs of volume (“VL”), the resulting Xe density in the lung [Xe]L will be - Thus, the concentration of Xe in the pulmonary blood [Xe]P will be related to the inhaled gas volume VXe, and can be stated by the expression:
For reference, an estimate of λ for Xe in blood is that 8≈0.15. Thus, as an example, a patient who inhales 1 L of Xe into his 6 L lung will yield a Xe density in the lungs of [Xe]L≈0.15 amagat, and correspondingly a Xe density in the pulmonary capillary beds of [Xe]P≈0.02 amagat. Thus, the dissolved polarized 129Xe gas in the pulmonary capillary beds will saturate at approximately ⅙ the concentration of the lung gas. - In certain embodiments, the present invention provides perfusion images that can be two (2) and three (3) dimensional multi-peak dissolved phase images of the perfusion in selected regions of the body such as the pulmonary vasculature or selected tissue in the brain (
FIG. 8B ) and the like. - As described in co-pending U.S. patent application Ser. No. 09/271,476, incorporated by reference as if recited in full herein, a patient who inhales 1 L of Xe into the lungs (having about a 6 L lung volume) will yield about or dissolve into about ⅙ of that value of the xenon concentration (0.02 amagat) in the pulmonary vasculature and associated blood. In certain embodiments, the method uses frequency selective large angle (more preferably 90°) RF excitation pulses that substantially deplete the 129Xe in the pulmonary blood but leave the hyperpolarized gas in the lungs substantially undisturbed to define the initial monitoring period during which dynamic NMR signal data is obtained. In this embodiment, the repetition time interval between RF pulses (TR) and the pulmonary blood flow rate (Q) can be used to determine the effective pulmonary volume (Veff) containing (dissolved phase) hyperpolarized 129Xe. This relationship assumes that TR is less than or substantially equal to the time it takes for the polarized 129Xe to leave the pulmonary blood (tp). As discussed above, for typical blood flow rate and estimated volume of venous pulmonary blood, tp is approximately 2.5 seconds. Thus, with a large RF excitation pulse (preferably, about α=90°), the dissolved pulmonary 129Xe signal strength in the pulmonary blood is proportional to the product of coil gain (“G”), Xe polarization (“Pxe”), and polarized Xe density or concentration in the vasculature ([Xe]P=λ[Xe]L), which can be stated by the following expression:
Sp(T R)=GP Xe8[Xe] L QT R. Equation (7) - Notably, the signal strength is dependent on both the pulse interval (TR) and the blood flow rate (Q). The dissolved signal intensity versus repetition time will have an associated slope which can be mathematically expressed as follows:
- The slope “m” of polarized xenon in the pulmonary blood is directly proportional to the pulmonary blood flow rate (Q). Calibration of the blood flow rate is obtainable by evaluating the gas phase signal (“SL”) in the lung, the signal having an associated small RF tipping angle (excitation angle) (“αL”). The gas phase signal can be expressed by the equation:
SL=GPXe[Xe]LVL sin αL. Equation (9) - The pulmonary blood flow rate (Q) can be stated by the ratio of the hyperpolarized 129Xe gas and dissolved phase signals. This ratio cancels receiver gain (G) and polarization value Pxe. Accordingly, the blood flow rate (Q) can be expressed by the following:
- Advantageously, with measurements of the Xe/blood partition coefficient (λ) and the total lung volume (VL), a quantitative measurement of blood flow is established according to a method of the instant invention. As will be appreciated by one of skill in the art, lung volume can be easily established to about 20% accuracy with techniques known to those of skill in the art. Preferably, techniques with relatively improved accuracy such as but not limited to spirometry are used.
- The spectroscopic evaluation methods do not require a polarization calibration because the measurement can be “self-calibrating.” Stated differently, the polarization can be cancelled by comparing dissolved and gaseous xenon signal, both of which can be assumed to have substantially the same or identical polarization to the extent that T1 relaxation in the blood is negligible, which it is for short TR settings as discussed above.
- The present invention has been described above with respect to particular preferred embodiments. Those skilled in the art, however, will appreciate that the invention can be employed for a broad range of applications. Methods for imaging or obtaining information about gas exchange barriers or environments and/or perfusion mapping using dissolved hyperpolarized 129Xe can be carried out according to the present invention using magnetic resonance or spectroscopic techniques known to those skilled in the art. See, e.g., U.S. Pat. No. 5,833,947; U.S. Pat. No. 5,522,390; U.S. Pat. No. 5,509,412′ U.S. Pat. No. 5,494,655, U.S. Pat. No. 5,352,979; and U.S. Pat. No. 5,190,744. See also Hou et al., Optimization of Fast Acquisition Methods for Whole-Brain Relative Cerebral Blood Volume (rCBV) Mapping with Susceptibility Contrast Agents, 9 J. Magnetic Resonance Imaging 233 (1999); Simonsen et al., CBF and CBV Measurements by USPIO Bolus Tracking: Reproducibility and Comparison with Gd-Based Values, 9 J. Magnetic Resonance Imaging 342 (1999); Mugler III et al., MR Imaging and Spectroscopy Using Hyperpolarized 129 Xe gas: Preliminary Human Results, 37 Magnetic Resonance in Medicine, pp. 809-815 (1997); Belliveau et al., Functional Cerebral Imaging by Susceptibility-Contrast NMR, 14 Magnetic Resonance in Medicine 14 538 (1990); Detre et al., Measurement of Regional Cerebral Blood Flow in Cat Brain Using Intracarotid 2 H 20 and 2 H NMR Imaging, 14 Magnetic Resonance in Medicine 389 (1990); Frank et al., Dynamic Dysprosium-DTPA-BMA Enhanced MRI of the Occipital Cortex; Functional Imaging in Visually Impaired Monkeys by PET and MRI (Abstract), Ninth Annual Scientific Meeting and Exhibition of the Society of Magnetic Resonance In Medicine (Aug. 18-24, 1990); Le Bihan, Magnetic Resonance Imaging of Perfusion, 14 Magnetic Resonance in Medicine 283 (1990); and Rosen et al., Perfusion Imaging by Nuclear Magnetic Resonance, 5 Magnetic Resonance Quarterly 263 (1989). The contents of these documents are hereby incorporated by reference as if recited in full herein.
- In particular embodiments, the present invention can be practiced to give a quantitative assessment of perfusion as will be appreciated by one of skill in the art. According to this embodiment, signal intensity can be followed over time as noted above. Examples of such quantitative relationships were developed for use with radioactive contrast agents with MR imaging and spectroscopy methods may be particularly suitable for dissolved phase 129Xe analysis of blood vessels. See, generally, Lassen, Cerebral Transit of an Intravascular Tracer may Allow Measurement of regional Blood Volume but not Regional Blood Flow, 4 J. Cereb. Blood Flow and Metab. 633 (1984).
- Furthermore, the inventive methods may be used for wide range of diagnostic and evaluative applications, as described herein.
- Other applications of the present invention include, but are not limited to: identification and assessment of the presence or absence and/or severity of cardiac ischemias and/or infarcts; localization and assessment of thrombi and plaques; determination of “therapeutic windows” for administering heparin, vasodilators, antihypertensive agents, calcium antagonists and the like, e.g., in reversible focal ischemia; monitoring of other induced vasodilator effects; detection and quantitative evaluation of the severity of ischemias; monitoring the vasodilatory or vasocontractory effects of a physiologically active substance; and monitoring surgically induced blood perfusion variations.
- The present invention may further be employed for: assessment of cerebral perfusion in following induced subarachnoid hemorrhage or in conditions marked by brain dysfunction, e.g., in connection with acute severe symptomatic hyponatremia; evaluation of new therapies, e.g., in the treatment of cerebral vasospasm (including but not limited to, anti-thrombolytic therapies, calcium channel blockers, anti-inflammatory therapies, angioplasty, and the like); assessment of the presence or absence and/or severity of ischemia in large tissue masses; assessment of the relationship between blood metabolites and cerebral perfusion in cerebral ischemia associated with acute liver failure, e.g., for the treatment of Alzheimer's disease; evaluation of new therapies for stroke, including but not limited to, t-PA, aspirin antiphospholipids, lupus anticoagulants, antiphospholipid antibodies, and the like; evaluation of risk factors for stroke, e.g., serum lipid levels; evaluation of induced brain hypothermia on cerebral perfusion during neurosurgery, e.g., for stroke; evaluation of the effects of age on cerebral perfusion, e.g., to study lacunar infarcts; and assessment of narcotics, e.g., cocaine, amphetamines, ethanol, and the like, on the ischemic brain.
- Many researchers have investigated characteristic chemical shifts observed when hyperpolarized 129Xe comes into contact with different tissues, as seen in Table 1. As shown, large frequency shifts (on the order of 200 parts per million or “ppm”) from free gas phase (referenced at 0 ppm) have been observed. This frequency shift is far greater than that observed with proton spectroscopy (generally stated, at most about 5 ppm). Therefore, spectroscopy is a modality which may be particularly suited to capitalize upon the behavior of hyperpolarized 129Xe.
TABLE 1 Characteristic shifts from free gaseous hyperpolarized 129Xe (referenced at 0 ppm) of hyperpolarized 129Xe when exposed to different tissues. Tissue ppm Reference Water 191.2 Wilson 99 Epicardial fat 192 Swanson 99 Brain, lipid rich 194 Albert 99 Brain tissue 194.5 Swanson 97 Plasma 195.6 Wilson 99 Brain 198.0 Wilson 99 Lung parenchyma 198.6 Wilson 99 Brain tissue 199 Swanson 99 Kidney 199.8 Wilson 99 Brain - lipid poor 201 Albert 99 Liver 201.8 Wilson 99 T. Californica membrane 209 Miller 81 RBC (oxygenated) 213.0 Wilson 99 RBC (de-oxygenated) 216.0 Albert 99 - As discussed hereinabove, hyperpolarized 129Xe can be administered to a patient by inhalation or injection. If the administration modality is injection, 129Xe can be suspended in a carrier fluid or injected directly such as in gaseous form. However, regardless of what tissue is of interest, if the 129Xe is suspended in a carrier fluid, it is likely that the carrier fluid itself distorts the results of the spectra and/or substantially obscures a spectral peak of interest. The carrier fluid may also react with the target tissue (region of interest) and/or potentially produce compounds with molecules in or around the tissue of interest, which may thereby cause the chemical shift of hyperpolarized 129Xe to differ from that which would be observed with merely the tissue of interest and hyperpolarized 129Xe. Therefore, direct injection of gaseous 129Xe or administration via inhalation may be particularly suitable for certain embodiments or applications. For additional discussion of direct injection of gaseous 129Xe, see co-pending U.S. application Ser. No. Ser. No. 09/804,369, the contents of which are hereby incorporated by reference as if recited in full herein.
- In certain embodiments, the spectral peaks may be quantified by normalizing the spectral data. The term “normalizing” means to adjust the signal data of the spectral peak or peaks of interest to account for selected signal variables. This adjustment may include using the mathematic ratio of the values of certain peaks associated with selected known biomatter (RBC, plasma, etc) within the response spectrum to quantify the hyperpolarized gas signal in the region of interest. The adjustment may include using the polarization level (and/or quantity) of the administered gas measured at the time of delivery to obtain a base or reference spectrum to quantify the magnitude of the signal. As such, the normalization can use relative data and/or absolute data. For example, the ratio of the spectra for the blood to spectra of the brain tissue (the ratio of the magnitude or area of selected spectral peaks) can be calculated. Of course, other known chemical shift peak locations can also be used to normalize the value of the spectra peak of interest. The absolute data can include data associated with the polarization level of the gas as it is delivered to the patient and/or the amount of gas administered thereto (to account for signal strength).
- A region-specific NMR coil can be positioned over the region of interest and to transmit a selected RF pulse sequence. The coil receives a FID signal. Localizing gradients can also be applied about the region of interest so as to localize the resonance region. For example, localizing gradients can be applied so that a desired region of interest is excited (either the left or right). In any event, the Fourier Transform of the acquired data is then calculated. The transformed signal data can be further processed which may include, but is not limited to, one or more of subtracting background noise, filtering undesirable signal data (such as those portions of the signal or spectra attributed to carrier liquids or deposits in non-target tissue or blood and the like), determining the frequency shift and size of the shift for any number of peaks within pre-determined ranges in the spectrum, and normalizing the data such as finding the ratios between magnitudes and/or areas of different spectral peaks within the response spectrum or accounting for polarization level and amount of polarized gas delivered to the subject. For further discussion of exemplary background subtraction or adjustment methods and cardiac gating methods, see co-pending U.S. application Ser. Nos. 09/271,476 and 09/271,476 incorporated by reference herein.
- The present invention finds use for both pre-clinical animal studies, veterinary and medical applications. The present invention may be advantageously employed for diagnostic evaluation and/or treatment of subjects, in particular human subjects, because it may be safer (e.g., less toxic) than other methods known in the art (e.g., radioactive methods). In general, the inventive methods may be more readily accepted because they avoid radioactivity or toxic levels of chemicals or other agents. Subjects according to the present invention can be any animal subject, and are preferably mammalian subjects (e.g., humans, canines, felines, bovines, caprines, ovines, equines, rodents, porcines, and/or lagomorphs), and more preferably are human subjects.
- The present invention is described with reference to flowchart illustrations and/or block diagrams of methods, and computer program products according to embodiments of the invention. It will be understood that each block of the flowchart illustrations and/or block diagrams, and combinations of blocks in the flowchart illustrations and/or block diagrams, can be implemented by computer program instructions. These computer program instructions may be provided to a processor of a general purpose computer, special purpose computer, embedded processor or other programmable data processing apparatus to produce a machine, such that the instructions, which execute via the processor of the computer or other programmable data processing apparatus, create means for implementing the functions specified in the flowchart and/or block diagram block or blocks.
- These computer program instructions may also be stored in a computer-readable memory that can direct a computer or other programmable data processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable memory produce an article of manufacture including instruction means which implement the function specified in the flowchart and/or block diagram block or blocks.
- The computer program instructions may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide steps for implementing the functions specified in the flowchart and/or block diagram block or blocks.
- As will be appreciated by one of skill in the art, the present invention may be embodied as a method, data or signal processing system, or computer program product. Accordingly, the present invention may take the form of an entirely software embodiment or an embodiment combining software and hardware aspects. Furthermore, the present invention may take the form of a computer program product on a computer-usable storage medium having computer-usable program code means embodied in the medium. Any suitable computer readable medium may be utilized including hard disks, CD-ROMs, optical storage devices, or magnetic storage devices.
- The computer-usable or computer-readable medium may be, for example but not limited to, an electronic, magnetic, optical, electromagnetic, infrared, or semiconductor system, apparatus, device, or propagation medium. More specific examples (a non-exhaustive list) of the computer-readable medium would include the following: an electrical connection having one or more wires, a portable computer diskette, a random access memory (RAM), a read-only memory (ROM), an erasable programmable read-only memory (EPROM or Flash memory), an optical fiber, and a portable compact disc read-only memory (CD-ROM). Note that the computer-usable or computer-readable medium could even be paper or another suitable medium upon which the program is printed, as the program can be electronically captured, via, for instance, optical scanning of the paper or other medium, then compiled, interpreted or otherwise processed in a suitable manner if necessary, and then stored in a computer memory.
- Computer program code for carrying out operations of the present invention may be written in an object oriented programming language such as Java7, Smalltalk or C++. However, the computer program code for carrying out operations of the present invention may also be written in conventional procedural programming languages, such as the “C” programming language or even assembly language. The program code may execute entirely on the user's computer, partly on the user's computer, as a stand-alone software package, partly on the users computer and partly on a remote computer or entirely on the remote computer. In the latter scenario, the remote computer may be connected to the user=s computer through a local area network (LAN) or a wide area network (WAN), or the connection may be made to an external computer (for example, through the Internet using an Internet Service Provider).
- The flowcharts and block diagrams illustrate methods to obtain dynamic NMR signal data and analyze and evaluate the data to (a) quantify the thickness of physiologic barriers such as structures or environments including tissue, membrane, or linings; (b) quantify the width of lumens or channels; (c) evaluate the adequacy of physiologic function of certain systems or membranes; (d) identify disruptions or compromised integrity of the barriers, structures, lumens, or channels and/or to identify disorders associated therewith; and (e) to provide perfusion map of the brain based on a concurrent acquisition of dynamic data at multiple chemical shifts associated with the brain across a plurality of compartments of the brain according to embodiments of the present invention. In this regard, each block in the flow charts or block diagrams represents a module, segment, or portion of code, which comprises one or more executable instructions for implementing the specified logical function(s). It should also be noted that in some alternative implementations, the functions noted in the blocks may occur out of the order noted in the figures. For example, two blocks shown in succession may in fact be executed substantially concurrently or the blocks may sometimes be executed in the reverse order, depending upon the functionality involved.
- The foregoing is illustrative of the present invention and is not to be construed as limiting thereof. Although a few exemplary embodiments of this invention have been described, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. Accordingly, all such modifications are intended to be included within the scope of this invention as defined in the claims. In the claims, means-plus-function clauses, where used, are intended to cover the structures described herein as performing the recited function and not only structural equivalents but also equivalent structures. Therefore, it is to be understood that the foregoing is illustrative of the present invention and is not to be construed as limited to the specific embodiments disclosed, and that modifications to the disclosed embodiments, as well as other embodiments, are intended to be included within the scope of the appended claims. The invention is defined by the following claims, with equivalents of the claims to be included therein.
Claims (43)
1. A minimally or non-invasive in vivo method for evaluating the thickness or width of a physiological barrier such as a membrane, lining, lumen, channel, or wall in a subject using dissolved-phase polarized 129Xe, comprising:
delivering polarized 129Xe gas in vivo to a subject having a first environment, a physiological barrier having a thickness, and a second environment opposing the first environment such that the polarized 129Xe travels serially through the first environment, the barrier, and into the second environment, wherein the polarized 129Xe has an associated different NMR signal chemical shift frequency in the first and second environments and the barrier; destroying the polarization of the 129Xe in the barrier and the second environment;
obtaining an NMR spectroscopic signal of the polarized gas in the subject at the second chemical shift to generate at least one dynamic data set of the NMR spectroscopic signal values over time representative of the behavior of the polarized 129Xe as it crosses the barrier and enters the second environment;
evaluating the polarized gas transit time of the polarized gas, the gas transit time corresponding to the time it takes the polarized gas to travel across the barrier and then enter the second environment, based on data provided by said obtaining step; and
determining the thickness or width of the barrier based on data provided by said evaluating step.
2. A method according to claim 2 , wherein the physiological barrier is the alveolar-capillary membrane, and wherein said obtaining and evaluating steps are carried out when the subject is at rest and then repeated while the subject is under stress by actual or simulated exercise to elevate the heart rate, and wherein said method further comprises comparing the gas transit times at rest and stress to thereby assess the function of the alveolar-capillary membrane.
3. A method according to claim 1 , wherein the step of determining is used to measure barriers having a thickness or width in the range of about 1 micron to about 100 microns.
4. A method according to claim 1 , wherein the first environment is the lung air space or pulmonary vasculature tissue, wherein the barrier comprises the alveolar-capillary membrane, and wherein the second environment is pulmonary blood.
5. A method according to claim 1 , wherein the physiological barrier is one of the glomerular capillary membrane, bowel membrane, placental membrane, and blood brain barrier.
6. A method according to claim 1 , wherein the obtaining step is carried out a plurality of times, including at least once while the subject is at rest and at least once when the subject is under actual or simulated physical activity.
7. A method according to claim 1 , wherein the obtaining and evaluating steps are carried out to monitor the efficacy of a therapeutic agent administered to the subject.
8. A method according to claim 1 , further comprising assessing the function of the alveolar-capillary membrane.
9. A method according to claim 1 , further comprising generating an MR image of the anatomy of interest using a dual tuned 129Xe and 1H RF excitation coil.
10. A method according to claim 1 , further comprising obtaining a polarized noble gas 129Xe ventilation distribution MRI.
11. A method according to claim 2 , further comprising determining the presence or absence of chronic heart failure based at least in part on said calculating step.
12. A method according to claim 1 , further comprising:
generating a signal strength versus time curve to fit the dynamic data;
identifying a time constant of the curve; and
evaluating the amplitude of the signal strength at a time along the curve corresponding to the time constant.
13. A method according to claim 1 , further comprising obtaining a second NMR spectroscopic signal of the polarized gas in the subject at the first chemical shift in the first environment to generate at least one dynamic data set of the NMR spectroscopic signal values over time; and generating a signal strength versus time curve to fit the dynamic data for the first environment.
14. A method according to claim 2 , further comprising evaluating pulmonary fibrosis or pulmonary edema.
15. A method according to claim 1 , further comprising evaluating at least one of glomerular filtration rate, acute and chronic renal failure, nephrotic syndrome, glomerulonephritis and other renal diseases.
16. A method according to claim 1 , further comprising evaluating large and small bowel wall thickness, integrity or function.
17. A method according to claim 1 , further comprising quantitatively evaluating placental membrane function.
18. A method according to claim 1 , further comprising evaluating the blood brain barrier.
19. A method according to claim 1 , further comprising evaluating the patient for respiratory ailments.
20. A method according to claim 9 , wherein said delivering step is carried out via breath-hold inhalation.
21. A method according to claim 1 , wherein the physiological barrier is a membrane or lining in the body of the subject.
22. A method according to claim 1 , wherein the physiological barrier is the bowel wall.
23. A method according to claim 1 , wherein the physiological barrier is the blood brain barrier.
24. A method according to claim 1 , further comprising evaluating organ or brain perfusion based at least in part on said obtaining and evaluating steps.
25. A method according to claim 1 , further comprising obtaining an NMR spectroscopic signal of the polarized gas in the subject at the first chemical shift to generate a second dynamic data set of the NMR spectroscopic signal values over time at the first chemical shift frequency, and wherein the first dynamic data defines a slope of the signal of polarized 129Xe in tissue over time in millisecond resolution, generating curves fit to each of the dynamic data sets.
26. A method according to claim 25 , wherein the second dynamic data set corresponds to polarized 129Xe behavior in tissue, and wherein the peak amplitude of the associated curve represents tissue volume.
27. A method according to claim 1 , further comprising generating a line of signal strength over time fit to the dynamic data, wherein the line has an associated time constant, an associated linear portion with a slope, and signal strength amplitude over time, and wherein said evaluating step considers parameters associated with the line, including at least one of, the time constant, the signal amplitude at a time corresponding to the time constant, the peak signal amplitude, and the slope associated with the linear portion of the curve.
28-33. (canceled)
34. A method of obtaining cerebral perfusion information, comprising:
administering polarized 129Xe to a subject in vivo;
concurrently obtaining a plurality dynamic data sets of NMR spectrographic signal strength of the polarized 129Xe in the brain of the subject representative of perfusion in the brain, each dynamic data set corresponding to a different chemical shift frequency;
repeating the obtaining step for a plurality of different compartments across the brain; and
generating at least one perfusion image of the brain based on the obtaining step, wherein the image comprises a plurality of voxels associated therewith, and wherein each voxel corresponds to a measure of perfusion in a predetermined number of compartmentalized regions in the brain.
35. A method according to claim 34 , wherein the dynamic data sets correspond to the dynamic behavior of polarized 129Xe in gray matter, polarized 129Xe in white matter, and polarized 129Xe in cerebral blood.
36. An in vivo method for evaluating at least one of the thickness of adequacy of function of a membrane or lining, comprising:
delivering polarized 129Xe in vivo to a subject such that the polarized 129Xe moves across the membrane or wall, the polarized gas in the membrane or wall having a corresponding polarized gas NMR chemical shift signal frequency;
obtaining an NMR spectroscopic signal of the polarized gas in the subject over time at the chemical shift frequency to generate at least one dynamic data set of the NMR spectroscopic signal strength values over time; and
evaluating at least one of (a) the adequacy of function of the membrane or lining and (b) determining the thickness of the membrane or lining based on the data provided by said obtaining step.
37. A method according to claim 36 , further comprising generating a line of signal strength over time best fit to the dynamic data, the line having an associated time constant, and wherein the step of obtaining is carried out for a time which is greater than about two times the length of the time constant.
38. A method according to claim 37 , wherein the evaluating step measures a membrane or lining with a thickness in the range of about 1 micron to about 100 microns.
39. A method according to claim 37 , wherein the membrane is the glomerular capillary membrane.
40. A method according to claim 37 , wherein the membrane is the bowel membrane.
41. A method according to claim 37 , wherein the membrane is the placental membrane.
42. A method according to claim 37 , wherein the membrane is the blood brain barrier.
43. A method according to claim 39 , wherein the function evaluated comprises measuring glomerular filtration rate.
44. A method according to claim 39 , wherein the method is used to monitor disease progression and therapy in subjects having one of glomerulonephritides, acute and chronic renal failure, nephrotic syndrome, and glomerulonephritis.
45. A method according to claim 40 , wherein the method is carried out to evaluate at least one of large and small bowel wall function.
46. A method according to claim 37 , wherein the evaluating step comprises assessing bowel membrane integrity and function for gastroenterological diseases.
47. A method according to claim 36 , wherein the obtaining step is carried out to monitor the efficacy of a therapeutic administered to the subject.
48. A computer program product for evaluating bioactivity, physiology, and/or perfusion in vivo in a subject, the computer program product comprising:
a computer readable storage medium having computer readable program code embodied in said medium, said computer-readable program code comprising:
computer readable program code that obtains an NMR spectroscopic signal of polarized 129Xe in the subject over time at at least one selected chemical shift frequency to generate at least one dynamic data set of the NMR spectroscopic signal strength values over time; and
computer readable program code that analyzes the dynamic data set for at least one of: (a) quantifying the thickness of a physiologic barrier such as tissue, membrane, or lining (b) quantifying the width of a lumen or channel; (c) evaluating the adequacy of physiologic function of certain biosystems or membranes; (d) identify disruptions or compromised integrity of physiological barriers, structures, lumens, or channels and/or to identify disorders associated therewith; and (e) to provide a cerebral perfusion map of the brain based on a concurrent acquisition of dynamic data at multiple chemical shifts associated with the brain across a plurality of compartments of the brain.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/224,204 US20060002856A1 (en) | 2001-09-20 | 2005-09-12 | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129Xe |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32377501P | 2001-09-20 | 2001-09-20 | |
US10/236,156 US6991777B2 (en) | 2001-09-20 | 2002-09-06 | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129 Xe |
US11/224,204 US20060002856A1 (en) | 2001-09-20 | 2005-09-12 | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129Xe |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/236,156 Division US6991777B2 (en) | 2001-09-20 | 2002-09-06 | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129 Xe |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060002856A1 true US20060002856A1 (en) | 2006-01-05 |
Family
ID=23260667
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/236,156 Expired - Fee Related US6991777B2 (en) | 2001-09-20 | 2002-09-06 | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129 Xe |
US11/224,204 Abandoned US20060002856A1 (en) | 2001-09-20 | 2005-09-12 | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129Xe |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/236,156 Expired - Fee Related US6991777B2 (en) | 2001-09-20 | 2002-09-06 | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129 Xe |
Country Status (6)
Country | Link |
---|---|
US (2) | US6991777B2 (en) |
EP (1) | EP1436637A1 (en) |
JP (1) | JP4283675B2 (en) |
AU (2) | AU2002332896B2 (en) |
CA (1) | CA2458901A1 (en) |
WO (1) | WO2003025606A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040142496A1 (en) * | 2001-04-23 | 2004-07-22 | Nicholson Jeremy Kirk | Methods for analysis of spectral data and their applications: atherosclerosis/coronary heart disease |
US20070093697A1 (en) * | 2005-10-21 | 2007-04-26 | Theranova, Llc | Method and apparatus for detection of right to left shunting in the cardiopulmonary vasculature |
US20150024416A1 (en) * | 2012-02-21 | 2015-01-22 | The University Of Warwick | Correction method for estimating free light chain production |
WO2017053799A1 (en) * | 2015-09-25 | 2017-03-30 | Oregon Health & Science University | Systems and methods for functional imaging of the placenta |
KR101774888B1 (en) | 2016-10-31 | 2017-09-06 | 가천대학교 산학협력단 | Pre-treatment apparatus for magnetic resonance spectroscopic data and method of pre-treatment for magnetic resonance spectroscopic data |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001056466A2 (en) * | 2000-02-02 | 2001-08-09 | The General Hospital Corporation | Method for evaluating novel stroke treatments using a tissue risk map |
US6915151B2 (en) * | 2001-02-08 | 2005-07-05 | Trustees Of The University Of Pennsylvania | Quantitative pulmonary imaging |
US7179450B2 (en) * | 2001-09-20 | 2007-02-20 | Medi-Physics, Inc. | Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe |
CA2458901A1 (en) * | 2001-09-20 | 2003-03-27 | Medi-Physics, Inc. | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129xe |
FR2848750B1 (en) * | 2002-12-13 | 2007-02-09 | Centre Nat Rech Scient | METHOD FOR ACQUIRING ELECTROMAGNETIC SIGNALS AND CONTRAST PRODUCT FOR SUCH ACQUISITION |
US7411396B1 (en) * | 2006-05-08 | 2008-08-12 | General Electric Company | Method and system of magnetic resonance spectroscopy with volume element dissection |
BRPI0718198A2 (en) * | 2006-10-03 | 2013-11-12 | Univ Duke | METHOD FOR PROVIDING PULMONARY GAS EXCHANGE STATE MRI DATA AND / OR CAPILLAR-ALVEOLAR BARRIER, MRI SCAN SYSTEM AND DEVICE, AND COMPUTER PROGRAM PRODUCT PRODUCT |
EP2157911A2 (en) * | 2007-05-16 | 2010-03-03 | Yeda Research And Development Co. Ltd. | Assessment of blood-brain barrier disruption |
WO2013057697A1 (en) | 2011-10-19 | 2013-04-25 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Magnetic resonance maps for analyzing tissue |
US9396528B2 (en) * | 2013-03-15 | 2016-07-19 | Digitalglobe, Inc. | Atmospheric compensation in satellite imagery |
EP2988668B1 (en) | 2013-04-24 | 2019-07-24 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Magnetic resonance maps for analyzing tissue |
US10677874B2 (en) * | 2018-02-20 | 2020-06-09 | Wisconsin Alumni Research Foundation | System and method for control of hyperpolarized gas-phase contamination in spectroscopic magnetic resonance imaging |
US11944424B2 (en) | 2018-05-18 | 2024-04-02 | Duke University | Dynamic 129Xe gas exchange spectroscopy |
CN114236443B (en) * | 2021-12-03 | 2023-07-18 | 中国科学院精密测量科学与技术创新研究院 | Gas MRI method for rapid quantitative assessment of dynamic ventilation function of lung |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545396A (en) * | 1994-04-08 | 1996-08-13 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
US6630126B2 (en) * | 2000-03-13 | 2003-10-07 | Medi-Physics, Inc. | Diagnostic procedures using direct injection of gaseous hyperpolarized 129Xe and associated systems and products |
US6991777B2 (en) * | 2001-09-20 | 2006-01-31 | Medi-Physics, Inc. | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129 Xe |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5494655A (en) * | 1990-03-09 | 1996-02-27 | The Regents Of The University Of California | Methods for detecting blood perfusion variations by magnetic resonance imaging |
US5190744A (en) * | 1990-03-09 | 1993-03-02 | Salutar | Methods for detecting blood perfusion variations by magnetic resonance imaging |
US5522390A (en) * | 1991-11-21 | 1996-06-04 | U.S. Philips Corporation | Magnetic resonance imaging method |
US5352979A (en) * | 1992-08-07 | 1994-10-04 | Conturo Thomas E | Magnetic resonance imaging with contrast enhanced phase angle reconstruction |
US5509412A (en) * | 1994-08-24 | 1996-04-23 | Wisconsin Alumni Research Foundation | Magnetic resonance imaging of blood volume |
CA2324269C (en) | 1998-03-18 | 2007-06-12 | Magnetic Imaging Technologies, Inc. | Mr methods for imaging pulmonary and cardiac vasculature and evaluating blood flow using dissolved polarized 129xe |
-
2002
- 2002-09-06 CA CA002458901A patent/CA2458901A1/en not_active Abandoned
- 2002-09-06 JP JP2003529182A patent/JP4283675B2/en not_active Expired - Fee Related
- 2002-09-06 EP EP02798934A patent/EP1436637A1/en not_active Withdrawn
- 2002-09-06 WO PCT/US2002/028430 patent/WO2003025606A1/en active Application Filing
- 2002-09-06 AU AU2002332896A patent/AU2002332896B2/en not_active Ceased
- 2002-09-06 US US10/236,156 patent/US6991777B2/en not_active Expired - Fee Related
-
2005
- 2005-09-12 US US11/224,204 patent/US20060002856A1/en not_active Abandoned
-
2009
- 2009-05-08 AU AU2009201836A patent/AU2009201836A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545396A (en) * | 1994-04-08 | 1996-08-13 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
US6630126B2 (en) * | 2000-03-13 | 2003-10-07 | Medi-Physics, Inc. | Diagnostic procedures using direct injection of gaseous hyperpolarized 129Xe and associated systems and products |
US6991777B2 (en) * | 2001-09-20 | 2006-01-31 | Medi-Physics, Inc. | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129 Xe |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040142496A1 (en) * | 2001-04-23 | 2004-07-22 | Nicholson Jeremy Kirk | Methods for analysis of spectral data and their applications: atherosclerosis/coronary heart disease |
US20070093697A1 (en) * | 2005-10-21 | 2007-04-26 | Theranova, Llc | Method and apparatus for detection of right to left shunting in the cardiopulmonary vasculature |
US20150024416A1 (en) * | 2012-02-21 | 2015-01-22 | The University Of Warwick | Correction method for estimating free light chain production |
WO2017053799A1 (en) * | 2015-09-25 | 2017-03-30 | Oregon Health & Science University | Systems and methods for functional imaging of the placenta |
KR101774888B1 (en) | 2016-10-31 | 2017-09-06 | 가천대학교 산학협력단 | Pre-treatment apparatus for magnetic resonance spectroscopic data and method of pre-treatment for magnetic resonance spectroscopic data |
Also Published As
Publication number | Publication date |
---|---|
CA2458901A1 (en) | 2003-03-27 |
JP4283675B2 (en) | 2009-06-24 |
EP1436637A1 (en) | 2004-07-14 |
WO2003025606A1 (en) | 2003-03-27 |
JP2005503221A (en) | 2005-02-03 |
AU2009201836A1 (en) | 2009-06-04 |
AU2002332896B2 (en) | 2009-05-28 |
US20030064023A1 (en) | 2003-04-03 |
US6991777B2 (en) | 2006-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060002856A1 (en) | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129Xe | |
US7867477B2 (en) | Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized 129Xe | |
US6491895B2 (en) | Methods for imaging pulmonary and cardiac vasculature and evaluating blood flow using dissolved polarized 129Xe | |
AU2002332896A1 (en) | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129 Xe | |
US7357917B2 (en) | Diagnostic procedures using 129Xe spectroscopy characterstic chemical shift to detect pathology in vivo | |
JP2003529420A (en) | Magnetic resonance imaging of the lung | |
JP2009106788A (en) | Polarized 129xe contrast agent for in vivo evaluation of respiratory organ disorder or cardiopulmonary disorder such as chronic heart failure | |
AU2002329991A1 (en) | Methods for in vivo evaluation of a physiological structure or function using polarized 129Xe | |
EP1286171A2 (en) | MR evaluation of vascular perfusion by means of hyperpolarized 129Xe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: POLAREAN INC., NORTH CAROLINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDI-PHYSICS INC.;REEL/FRAME:028509/0240 Effective date: 20111219 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |